MRC-Asthma UK Centre in Allergic Mechanisms of Asthma

Lead Research Organisation: Imperial College London
Department Name: National Heart and Lung Institute

Abstract

Allergy affects 1 in 6 people in the UK and Asthma affects 1 in 12 of the population in the UK, with 5.4 million people currently receiving treatment. The UK has one of the highest prevalences of asthma in young adults in Europe and the numbers of children reporting asthma symptoms has risen six fold over the last 30 years. Asthma costs the NHS almost #1bn per year and it is estimated that at least 12.7 million working days are lost due to asthma each year. This health and economic burden on the nation emphasizes the importance of research that tries to understand the diseases. The current proposal for a Centre brings together a group of doctors and scientists to discover new ways to prevent, treat and cure allergy and asthma.

Technical Summary

The prevalence of allergic disease in the UK is amongst the highest in the world and that of asthma in young adults is the highest in Europe. The Centre is a partnership between the MRC, Asthma UK, Imperial, QMUL and KCL. The mission of the Centre is to understand allergic mechanisms of asthma to inform the development of new treatments; to create a high quality environment for research training; and to be an authoritative voice on allergy and asthma in the public domain. In the last five years the Centre has successfully established a critical mass of researchers working co-ordinately in an internationally competitive unit for the benefits of health care. It has established core facilities, thereby focussing resources. The Centre has provided enhanced opportunities for new collaborative programmes of work to be started with even greater potential for more competitive funding, which would not otherwise be possible. The Centre has made substantial progress in each of the domains contained in its mission statement, namely in scholarship, training and public engagement. It has brought researchers together under an integrated strategy for allergy and asthma research which is unique in the UK. The research network has facilitated the conduct of translational science from the womb to adulthood and from the gene to the community.

Organisations

Publications

10 25 50

publication icon
Adcock IM (2017) Glucocorticoids. in Handbook of experimental pharmacology

publication icon
Adcock IM (2012) Strategies for improving the efficacy and therapeutic ratio of glucocorticoids. in Current opinion in pharmacology

publication icon
Afzali B (2011) Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells. in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

publication icon
Ali K (2016) Antenatal substance misuse and smoking and newborn hypoxic challenge response. in Archives of disease in childhood. Fetal and neonatal edition

 
Description Advances in mechanisms of allergy and clinical immunology in 2012
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical reviews
 
Description Asthma patient passport
Geographic Reach National 
Policy Influence Type Citation in other policy documents
Impact The asthma passport enables patients with sever asthma who are prone to repeated hospital admissions to present a plan of "best care" agreed with the care team and revised regularly, so that help is delivered much mire quickly and patients are less fearful about attending A&E departments, a major factor identified in the recent RCP National review if Asthma deaths in contributing to asthma mortality.
 
Description Changes in guidelines for prevention of peanut allergy
Geographic Reach North America 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description EAACI Allergen-specific Immunotherapy Guidelines for Food Allergy
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description EAACI Allergen-specific Immunotherapy Guidelines for Prevention of Allergic Disease
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description EAACI Task Force on Allergen Thresholds
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description EAACI Task Force on the impact of food processing on food allergy
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description EAACI Task-Force on allergic diseases in adolescents and young people, towards better patient-centred care
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description EAACI Taskforce on the external quality assurance of the basophil activation test
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description Editorial in the European Respiratory Journal (ERJ 2016;48:1538-1540)
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical reviews
 
Description Guidelines for food allergy and weaning
Geographic Reach Multiple continents/international 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
 
Description IUPHAR review
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in systematic reviews
 
Description Leader of guidelines on severe Asthma under ERS/ATS
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
Impact Imrpoved outcomes for severe asthma
 
Description MM is a member of the Microbiome Expert Working Group - organised by the Microbiology Society to: inform and contribute to the development of an accessible, evidence-based report/collection of briefings for policy- and decision-makers exploring human, animal and environmental microbiome research and its relevance to public policy.
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Mast Cell, Basophil & Eosinophil expert group of NIAID Asthma and Allergy Network Summit meeting
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Guideline Title Global Initiative for Asthma
Description Mentioned in GINA guidelines for amangement of severe asthma
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
Impact Better outcomes for severe asthma
 
Guideline Title To be publsihed
Description NICE consultation on management of asthma in the community
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Description RASP-UK
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description (Sustaining Health) - Environmental and nutritional interventions for improving - FK
Amount £15,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2014 
End 08/2016
 
Description A Byrne - How does airway macrophage glycolytic reprogramming contribute
Amount £96,063 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 01/2019
 
Description A Byrne - Investigating the role of innate glycolytic reprogramming in asthma
Amount £219,492 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2017 
End 10/2020
 
Description A Pilot study to determine dose-response characteristics and identify local and peripheral biomarkers following cat allergen
Amount £272,009 (GBP)
Organisation Immune Tolerance Network 
Sector Charity/Non Profit
Country United States
Start 02/2013 
End 03/2014
 
Description AB - Global Health Sara-Jane Smith
Amount £44,970 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 08/2018
 
Description AG - eLIXIR, Early Lifecourse data Cross-Linkage in Research; a Multidisciplinary Partnership
Amount £867,365 (GBP)
Funding ID MR/P003060/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 02/2017 
End 01/2020
 
Description AP07 substrate-selective LTA4H inhibitor - Phase 2 lead optimisation
Amount £280,000 (GBP)
Organisation Apollo Therapeutics 
Sector Private
Country United Kingdom
Start 03/2018 
End 10/2018
 
Description AZ- EU-IMI project
Amount £101,000 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start  
 
Description AZALEA Azithromycin against placebo in exacerbatiosn of asthma
Amount £1,444,859 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 08/2011 
End 02/2015
 
Description Action Medical Research Grant
Amount £150,000 (GBP)
Organisation Action Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Alpha 1 Foundation Research Funding
Amount £28,000 (GBP)
Organisation Alpha-1 Foundation 
Sector Charity/Non Profit
Country United States
Start 10/2014 
End 06/2015
 
Description Alzheimer's Research UK
Amount £715,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2010 
End 05/2015
 
Description Anti-viral properties of novel macrolide antibiotics
Amount £80,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2010 
End 10/2014
 
Description Assessment of alveolar macrophage responses to inhaled particulate medicines
Amount £55,050 (GBP)
Funding ID NC/C013111/1 
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Private
Country United Kingdom
Start 01/2014 
End 06/2014
 
Description Assessment of severity of cardiopulmonary abnormalities in extremely prematurely born infants - AG
Amount £75,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 10/2013 
End 09/2014
 
Description Asthma UK
Amount £18,500 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2011 
End 09/2012
 
Description Asthma UK
Amount £50,000 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2012
 
Description Asthma UK
Amount £33,000 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2010 
End 09/2011
 
Description Asthma UK
Amount £31,107 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2011 
End 04/2012
 
Description Asthma UK - prof.chair
Amount £1,146,773 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2011 
End 08/2016
 
Description Asthma UK Centre for Allergic Mechanisms in Asthma
Amount £1,999,074 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2016 
End 07/2021
 
Description Asthma UK Chair
Amount £1,146,773 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2011 
End 08/2016
 
Description Asthma UK Professorship
Amount £1,146,793 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2011 
End 08/2016
 
Description Asthma UK Project Grant
Amount £49,754 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2018
 
Description Asthma UK grant
Amount £49,726 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 10/2012
 
Description Asthma UK grant
Amount £49,279 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2011 
End 08/2012
 
Description Asthma UK grant
Amount £50,000 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2012
 
Description B cell repertoire and allergen-specificity during sublingual allergen immunotherapy. - SD
Amount £330,000 (GBP)
Organisation ALK-Abelló A/S 
Sector Private
Country Denmark
Start 02/2014 
End 01/2017
 
Description BBSRC
Amount £458,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2010 
End 12/2013
 
Description BBSRC -CASE PhD
Amount £80,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2010 
End 08/2014
 
Description BBSRC CASE award (Waters plc)
Amount £19,200 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2016 
End 09/2020
 
Description BBSRC Project Grant
Amount £292,546 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2020
 
Description BBSRC and UCB grant
Amount £167,253 (GBP)
Organisation Rothamsted Research 
Sector Academic/University
Country United Kingdom
Start 10/2012 
End 09/2016
 
Description BBSRC grant
Amount £458,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2010 
End 11/2013
 
Description BHF grant
Amount £279,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2012 
End 01/2014
 
Description BLF Fellowship
Amount £120,000 (GBP)
Organisation British Lung Foundation (BLF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2009 
End 12/2011
 
Description BLF Pump-Priming Grant
Amount £25,000 (GBP)
Funding ID PPRG15-9 
Organisation British Lung Foundation (BLF) 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2015 
End 05/2017
 
Description BMA James Trust
Amount £44,000 (GBP)
Organisation British Medical Association (BMA) 
Sector Learned Society
Country United Kingdom
Start 08/2009 
End 07/2011
 
Description BMA grant
Amount £55,000 (GBP)
Funding ID P47006 
Organisation British Medical Association (BMA) 
Sector Learned Society
Country United Kingdom
Start 09/2014 
End 08/2016
 
Description BRC grant
Amount £66,378 (GBP)
Organisation National Institute for Health Research 
Department NIHR Imperial Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 04/2012 
End 03/2017
 
Description BRC grant
Amount £143,418 (GBP)
Organisation National Institute for Health Research 
Department NIHR Imperial Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 09/2009 
End 08/2011
 
Description Barbara Bartlett Hodgkins Disease Bequest
Amount £145,000 (GBP)
Organisation King's College London 
Sector Academic/University
Country United Kingdom
Start 06/2011 
End 05/2014
 
Description Boehringer Ingelheim funding -MB
Amount £360,000 (GBP)
Organisation Boehringer Ingelheim 
Sector Private
Country Germany
Start 01/2011 
End 01/2013
 
Description CASE Studentship
Amount £62,116 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2011 
End 09/2014
 
Description CASE Studentship
Amount £60,000 (GBP)
Organisation Novartis 
Sector Private
Country Global
Start 10/2011 
End 09/2014
 
Description CASE studentship
Amount £28,000 (GBP)
Organisation Novartis 
Sector Private
Country Global
Start 10/2011 
End 09/2014
 
Description CASE studentship
Amount £27,500 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2011 
End 09/2014
 
Description CH - The immunological effects of vitamin D obtained by UVR versus supplementation
Amount £9,968 (GBP)
Organisation Skin Analytics 
Sector Private
Country United Kingdom
Start 07/2017 
End 06/2019
 
Description CL - NHLI Foundation Centre for Airways Disease in Children & Young Adults
Amount £3,500,000 (GBP)
Organisation National Heart and Lung Institute Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2023
 
Description COPE: Characterisation of COPD Exacerbations using Environmental Exposure Modelling-FK
Amount £226,718 (GBP)
Funding ID MR/L019744/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2014 
End 09/2017
 
Description Can vitamin D protect airways from inflammation due to particulate matter air pollution that would otherwise drive asthma?
Amount £162,161 (GBP)
Funding ID 098882/Z/12/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2012 
End 10/2014
 
Description Cell mediated immunity against RSV and influenza in a human experimental challenge model -po
Amount £1,334,395 (GBP)
Funding ID G0902266 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2010 
End 11/2014
 
Description Changing patterns of place of cancer deaths in children and young people 1984-2010 - AG
Amount £59,484 (GBP)
Organisation Marie Curie 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2013 
End 09/2014
 
Description Characterise the effect of the long acting beta2 adrenoceptor agonist BI 1744 CL on airway sensory nerves - MB
Amount £707,186 (GBP)
Organisation Boehringer Ingelheim 
Sector Private
Country Germany
Start 06/2010 
End 10/2014
 
Description Chromatin architecture, transcriptomics and epigenetics in inflammatory disease. - PL
Amount £120,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Comprehensive Biomedical Research Centre, Guy's and St Thomas
Sector Public
Country United Kingdom
Start 10/2012 
End 09/2017
 
Description Clinical Resarch Fellowship A. Singanayagam
Amount £248,724 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2014
 
Description Clinical utility and feasibility of the multiple breath washout technique and offline exhaled nitric oxide in preschool wheezing disorders-AB
Amount £39,454 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2014 
End 09/2015
 
Description Clinician Scientist Award
Amount £450,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description Cognitive DeveLopment in the Urban Environment (The CLUE study)
Amount £618,056 (GBP)
Funding ID MR/R00322X/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2018 
End 12/2020
 
Description Component-Specific Air pollutant Drivers of Disease Risk in Early to Midlife: a pathway approach. (DREaM)
Amount £1,285,073 (GBP)
Funding ID NE/T001895/1 
Organisation Natural Environment Research Council 
Sector Public
Country United Kingdom
Start 02/2019 
End 02/2022
 
Description Consumables funds - sub-project to WHRD_P43493-AB
Amount £22,800 (GBP)
Organisation Royal Brompton & Harefield NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 03/2013 
End 02/2014
 
Description Contribution of Innate Lymphoid cells to steroid resistance in paediatric asthma - CL
Amount £49,500 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2014 
End 07/2016
 
Description Controlling Th17 responses in alpha 1 antitrypsin deficiency
Amount $40,000 (USD)
Organisation Alpha-1 Foundation 
Sector Charity/Non Profit
Country United States
Start 02/2017 
End 01/2018
 
Description DEMiSt - The Diesel Exposure Mitigation Study
Amount £145,832 (GBP)
Organisation Institution of Occupational Safety and Health (IOSH) 
Sector Learned Society
Country United Kingdom
Start 07/2017 
End 06/2019
 
Description Defining the importance of IL-25 in rhinovirus induced asthma exacerbations - SJ
Amount £274,027 (GBP)
Funding ID G1100168 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 11/2011 
End 03/2014
 
Description Describing habitual levels of physical activity (PA) in older people in terms of impact loads and how this relates to bone and other systems. -Seif
Amount £836,039 (GBP)
Funding ID MR/K024973/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2013 
End 09/2016
 
Description Design and evaluation of simulated human lung lining fluid
Amount £24,000 (GBP)
Funding ID STU029547 
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 10/2010 
End 09/2014
 
Description Development of a Programme of Human Nasal Challenge Models with Constituents of Viruses, Bacteria, Tuberculosis and Allergens - po
Amount £568,695 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2013 
End 03/2017
 
Description Developmental pathway of IgE-secreting plasma cells: prospective targets for the treatment of asthma-DF
Amount £179,394 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2014 
End 12/2016
 
Description Differentiating alveolar macrophage responses to inhaled medicines
Amount £1,000,000 (GBP)
Funding ID NC/C013203/1 
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Private
Country United Kingdom
Start 10/2014 
End 09/2017
 
Description Discovery project_HRV vac
Amount £483,465 (GBP)
Funding ID AP09_Discovery project_HRV vac 
Organisation Apollo Therapeutics 
Sector Private
Country United Kingdom
Start 09/2017 
End 03/2019
 
Description Do we need to reduce threshold limits for air pollution? An epidemiological study on epigenetic pathways leading to lung cancer - FK
Amount £106,010 (GBP)
Organisation The Colt Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2014 
End 02/2016
 
Description Do we need to reduce threshold limits for air pollution? An epidemiological study on epigenetic pathways leading to lung cancer - FK
Amount £106,010 (GBP)
Organisation The Colt Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2014 
End 02/2016
 
Description DoH grant
Amount £1,970,000 (GBP)
Organisation Department of Health (DH) 
Sector Public
Country United Kingdom
Start 01/2012 
End 01/2013
 
Description Does a peanut, tree-nut or sesame seed allergy necessitate the avoidance of all nuts and seeds? (ProNUTS)-GL
Amount £150,000 (GBP)
Organisation Food Allergy Research and Education (FARE) 
Sector Charity/Non Profit
Country United States
Start  
 
Description Dunhill Medical Trust Grant
Amount £54,216 (GBP)
Funding ID SA29/0513 
Organisation The Dunhill Medical Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2013 
End 09/2015
 
Description EAACI
Amount € 5,000 (EUR)
Funding ID Dr Aikaterini Chairakaki 
Organisation European Academy of Allergy and Clinical Immunology (EAACI) 
Sector Learned Society
Country European Union (EU)
Start 01/2011 
End 03/2011
 
Description EACCI Winter School Travel grant
Amount € 250 (EUR)
Organisation European Academy of Allergy and Clinical Immunology (EAACI) 
Sector Learned Society
Country European Union (EU)
Start 02/2015 
End 02/2015
 
Description EFIS (European Federation of Immunological Societies) Travel Grant
Amount € 600 (EUR)
Organisation European Federation of Immunological Societies (EFIS) 
Sector Charity/Non Profit
Country European Union (EU)
Start 09/2015 
End 09/2015
 
Description ERC Advanced Grant
Amount £2,000,000 (GBP)
Organisation European Research Council (ERC) 
Sector Public
Country European Union (EU)
Start  
 
Description EXPOsOMICS
Amount £7,199,367 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start  
 
Description Enhancing clinical practice: addressing health inequalities for people with intellectual disabilities in South London - AG
Amount £60,000 (GBP)
Organisation Health Education England 
Department Health Education South London
Sector Public
Country United Kingdom
Start 10/2014 
End 09/2016
 
Description Establishing and integrated approach to optimising medicines: scoping the requirements - AG
Amount £70,000 (GBP)
Organisation Guy’s & St Thomas’ Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2013 
End 09/2014
 
Description European Asthma Research and Innovation Partnership - SJ
Amount £450,000 (GBP)
Organisation European Commission 
Department Seventh Framework Programme (FP7)
Sector Public
Country European Union (EU)
Start 09/2013 
End 08/2016
 
Description Exogenous sex steroid hormones and asthma in females of reproductive age: a population-based prospective cohort study using the Optimum Patient Care Research Database (OPCRD)
Amount £50,000 (GBP)
Funding ID AUK-IG-2016-346 
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 03/2018
 
Description FC - Inhibition of muscle wasting by LNA antagomiRs
Amount £38,691 (GBP)
Organisation Apollo Therapeutics 
Sector Private
Country United Kingdom
Start 10/2017 
End 10/2018
 
Description FK - Advanced UK Observing Network For Air Quality, Public Heath and Greenhouse Gas Research
Amount £4,296,371 (GBP)
Funding ID NE/R011532/1 
Organisation Natural Environment Research Council 
Sector Public
Country United Kingdom
Start 08/2017 
End 08/2022
 
Description FK - Health1UP2 - Differentiated health impacts of primary and secondary ultrafine particles
Amount £139,426 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 09/2017 
End 09/2019
 
Description FSA grant
Amount £2,091,260 (GBP)
Organisation Food Standards Agency (FSA) 
Sector Public
Country United Kingdom
Start 01/2008 
End 05/2015
 
Description Foundation Grant
Amount £18,500 (GBP)
Funding ID 11/040 
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2012
 
Description Foundation grant
Amount £90,000 (GBP)
Organisation Lord Leonard and Lady Estelle Wolfson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2014 
End 03/2017
 
Description GL - Effects of early introduction of allergenic foods followed by ad-libitum consumption on food allergic sensitisation at 8 years of age in exclusively breastfed infants
Amount £151,338 (GBP)
Organisation Action Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2017 
End 05/2020
 
Description GSTT
Amount £140,000 (GBP)
Organisation Guy's and St Thomas' NHS Foundation Trust 
Department Guy’s and St Thomas’ Kidney Patients' Association (GSTT KPA)
Sector Charity/Non Profit
Country United Kingdom
Start 03/2012 
End 02/2014
 
Description Genetic and Functional Characterization of the IgE Repertoire and Compartmental Regulation of IgE Activity in the Pathogenesis of Asthma
Amount £764,786 (GBP)
Funding ID MR/M022943/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2015 
End 04/2018
 
Description Genetics of malignant mesothelioma - MM
Amount £199,998 (GBP)
Organisation British Lung Foundation (BLF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2013 
End 09/2016
 
Description Guy' and St Thomas' Chrity grant
Amount £261,554 (GBP)
Organisation Guy’s & St Thomas’ Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2011 
End 05/2013
 
Description Guy's and St Thomas' NHS Foundation Trust - HG
Amount £500,000 (GBP)
Organisation Guy's and St Thomas' NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 11/2008 
End 03/2012
 
Description Guy's and St Thomas' NHS Foundation Trust funding
Amount £1,000,000 (GBP)
Organisation Guy's and St Thomas' NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 04/2010 
End 03/2013
 
Description Guy's and St. Thomas' Charity Clinical Translational Award Scheme
Amount £370,000 (GBP)
Organisation Guy’s & St Thomas’ Charity 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Guy's and St.Thomas' Charitable Foundation
Amount £250,000 (GBP)
Organisation Guy’s & St Thomas’ Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2010 
End 06/2013
 
Description HEFCE
Amount £250,000 (GBP)
Organisation Higher Education Funding Council for England 
Sector Public
Country United Kingdom
Start 05/2011 
End 04/2016
 
Description HG - Long-lived IgE+ plasma cells as a new therapeutic target for treatment of allergies and asthma
Amount £80,754 (GBP)
Organisation King’s Health Partners 
Sector Academic/University
Country United Kingdom
Start 06/2017 
End 06/2018
 
Description Health Protection Research Unit (HPRU) in Respiratory Infections -SJ
Amount £20,335 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2014 
End 03/2019
 
Description Health Protection Research Unit - Health Impact of Environmental Hazards-FK
Amount £1,228,804 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2014 
End 03/2019
 
Description Health Technology Assessment Programme
Amount £2,000,000 (GBP)
Organisation National Institute for Health Research 
Department Health Technology Assessment Programme (HTA)
Sector Public
Country United Kingdom
Start 07/2012 
End 06/2014
 
Description Healthcare Quality Improvement Partnership
Amount £545,000 (GBP)
Organisation The Health Quality Improvement Partnership (HQIP) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2011 
End 01/2014
 
Description High-resolution crystallographic structural analysis of low molecular weight compounds - BS
Amount £168,010 (GBP)
Organisation UCB Pharma 
Sector Private
Country United Kingdom
Start 01/2014 
End 01/2015
 
Description Human Infection Challenge Vaccine (HIC-Vac) network.
Amount £3,000,000 (GBP)
Funding ID MR/R005982/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2017 
End 07/2021
 
Description IA - Donnelly - Multi User Equipment Grant
Amount £264,250 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 08/2022
 
Description ICIC - TRPV4 antagonist: novel, effective treatment for asthma and COPD - RB
Amount £35,226 (GBP)
Organisation Imperial Innovations 
Sector Private
Country United Kingdom
Start 07/2014 
End 03/2015
 
Description Identification of the CCL18 receptor - JP
Amount £43,500 (GBP)
Organisation Royal Embassy of Saudi Arabia 
Sector Public
Country United States
Start  
 
Description IgG blocking activity: relation to conjunctival provocation test after allergen immunotherapy. - SD
Amount £300,000 (GBP)
Organisation BioTech Tools 
Sector Private
Country Belgium
Start 04/2014 
End 03/2015
 
Description Immune Function and Pathology Dissected by High Throughput Analysis of Mice with Targeted Gene Disruptions: An investigation by the Infection and Immunity Immunophenotyping (3I) Consortium - CL
Amount £4,906,954 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2013 
End 12/2017
 
Description Immune Tolerance Network/NIH
Amount £54,870 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 04/2011 
End 09/2011
 
Description Immune Tolerance Network/NIH
Amount £1,950,000 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 03/2011 
End 02/2015
 
Description Immunological consequences of vitamin D obtained by UVR vs. supplementation
Amount £9,968 (GBP)
Funding ID S1220 
Organisation British Skin Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2017
 
Description Immunotherapy for cat allergy: biomarkers of tolerance - SD
Amount £497,000 (GBP)
Organisation Regeneron Pharmaceuticals, Inc. 
Sector Private
Country United States
Start 10/2014 
End 09/2015
 
Description Impact urban particulate matter on dendritic cell function
Amount £20,000 (GBP)
Organisation Inman Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2019
 
Description Imperial College Healthcare NHS Trust- Biomedical Research Centre (BRC) funding
Amount £143,418 (GBP)
Organisation National Institute for Health Research 
Department NIHR Imperial Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 09/2009 
End 01/2012
 
Description Imperial Innovations Proof Of Concept
Amount £30,000 (GBP)
Funding ID 2543 
Organisation Imperial Innovations 
Sector Private
Country United Kingdom
Start 07/2015 
End 06/2016
 
Description Imperial Innovations Proof Of Concept
Amount £32,296 (GBP)
Funding ID 6359 
Organisation Imperial Innovations 
Sector Private
Country United Kingdom
Start 12/2015 
End 05/2016
 
Description Improving communication with the public about antivirals and vaccination during the next pandemic-FK
Amount £1,860 (GBP)
Organisation Department of Health Social Services and Public Safety (DHSSPS) 
Sector Public
Country United Kingdom
Start 09/2013 
End 08/2015
 
Description In vivo and in vitro testing of a novel pan JAK/STAT inhibitor.
Amount £139,734 (GBP)
Organisation Vectura Ltd 
Sector Private
Country United Kingdom
Start 02/2014 
End 02/2015
 
Description Industrial collaboration
Amount £164,139 (GBP)
Organisation UCB Pharma 
Sector Private
Country United Kingdom
Start 02/2018 
End 02/2019
 
Description Interaction of histamine-releasing gator with immunoglobulins in asthma - HG
Amount $405,000 (USD)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start  
 
Description Investigate the role of JAK in models of airway disease - MB
Amount £351,073 (GBP)
Organisation Pfizer Ltd 
Sector Private
Country United Kingdom
Start 06/2014 
End 06/2016
 
Description Investigating the impact of London's Ultra Low Emission Zone on children's respiratory health
Amount £237,130 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2018 
End 12/2023
 
Description Investigation into the role of extracellular vesicle in exacerbation of lung diseases - MB
Amount £9,460 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2014 
End 02/2016
 
Description JMD - Elucidating the mechanisms of accelerated dissociation and allosteric processes in the antibody immunoglobulin E
Amount £292,546 (GBP)
Funding ID BB/P000436/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 01/2017 
End 12/2019
 
Description JMD - King's NMR Facility for structural biology, metabolic profiling and drug discovery
Amount £1,000,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 12/2021
 
Description JMD - King's NMR Facility for structural biology, metabolic profiling and drug discovery
Amount £1,000,000 (GBP)
Organisation University of Glasgow 
Department British Heart Foundation Unit
Sector Academic/University
Country United Kingdom
Start 01/2017 
End 12/2021
 
Description JP - Therapeutic potential of Coversin in a mouse model of allergic airways disease - Akari Therapeutics PLC
Amount £122,818 (GBP)
Organisation Akari Therapeutics 
Start 01/2017 
End 02/2018
 
Description King's College London KCL health partners
Amount £48,961 (GBP)
Organisation King’s Health Partners 
Sector Academic/University
Country United Kingdom
Start 09/2012 
End 08/2014
 
Description King's College London KCL health pratners
Amount £72,415 (GBP)
Organisation King’s Health Partners 
Sector Academic/University
Country United Kingdom
Start 09/2012 
End 08/2013
 
Description King's Health Partners Fellowship
Amount £100,000 (GBP)
Organisation King’s Health Partners 
Department King's Health Partners Research and Development Challenge Fund
Sector Charity/Non Profit
Country United Kingdom
Start 07/2015 
End 06/2016
 
Description King's Health Partners Research Grant (Ramadani)
Amount £80,754 (GBP)
Organisation King’s Health Partners 
Sector Academic/University
Country United Kingdom
Start 06/2017 
End 06/2018
 
Description Lab consumables - BM
Amount £440,000 (GBP)
Organisation Imperial College London 
Department Imperial College Trust
Sector Charity/Non Profit
Country United Kingdom
Start 12/2012 
End 11/2015
 
Description Life Study: Core Scientific & Management Team Award - FK
Amount £29,749 (GBP)
Organisation Economic and Social Research Council 
Sector Public
Country United Kingdom
Start 03/2013 
End 11/2019
 
Description London Law trust
Amount £120,000 (GBP)
Organisation London Law Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2010 
End 02/2012
 
Description Long-term effects of sublingual and subcutaneous grass pollen immunotherapy in severe hay fever (Single Centre Study). 5 years mechanistic study of tolerance induction in allergy - SD
Amount £3,380,000 (GBP)
Organisation Immune Tolerance Network 
Sector Charity/Non Profit
Country United States
Start 04/2011 
End 03/2016
 
Description MB - Optimizing EP receptor subtype targeting for asthma therapy
Amount £90,401 (GBP)
Organisation Thomas Jefferson University 
Sector Academic/University
Country United States
Start 02/2017 
End 01/2018
 
Description MICA - Investigation into the mechanisms that drive cough in health and disease - MB
Amount £664,770 (GBP)
Funding ID MR/K020293/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2013 
End 04/2016
 
Description MICA: Investigation into the mechanisms that drive cough in health and disease
Amount £15,000 (GBP)
Organisation Almirall 
Sector Private
Country Spain
Start 05/2013 
End 04/2016
 
Description MRC / ABPI initiative
Amount £330,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC / Asthma UK centre grant
Amount £2,277,091 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC Career Development Award Cecilia Johansson PhD - Regulation of interferon production in the lung during RSV infection - CJ
Amount £1,086,829 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2009 
End 07/2015
 
Description MRC Centenary Award
Amount £22,500 (GBP)
Organisation King's College London 
Department MRC & Asthma UK Centre in Allergic Mechanisms of Asthma
Sector Academic/University
Country United Kingdom
Start 04/2013 
End 09/2013
 
Description MRC Centre Capital Award
Amount £44,700 (GBP)
Organisation Medical Research Council (MRC) 
Department MRC Clinical Research Infrastructure Initiative
Sector Public
Country United Kingdom
Start 12/2013 
End 03/2014
 
Description MRC EMINENT grant
Amount £8,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2016 
End 01/2021
 
Description MRC Fellowship (Santos)
Amount £1,483,513 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2015 
End 07/2020
 
Description MRC Grant
Amount £368,267 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2010 
End 04/2012
 
Description MRC Programme Grant
Amount £2,019,424 (GBP)
Funding ID P41413 MRC JOHNSTON 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2012 
End 11/2017
 
Description MRC Programme grant LIFE Study
Amount £28,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2011 
End 06/2017
 
Description MRC Project
Amount £64,281 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 02/2018 
End 01/2019
 
Description MRC Project
Amount £774,182 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2015 
End 12/2018
 
Description MRC Research Grant (G0501746 Molecular biology and cellular mechanisms of aspirin sensitive respiratory disease)
Amount £350,000 (GBP)
Funding ID G0501746 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2010 
End 05/2013
 
Description MRC and GSK alliance
Amount £4,317,023 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC and NIHR grant
Amount £1,284,288 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC and Novartis
Amount £91,500 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2010 
End 09/2013
 
Description MRC clinician
Amount £1,259,288 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC grant
Amount £762,064 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2012 
End 08/2015
 
Description MRC grant
Amount £72,018 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2011 
End 11/2016
 
Description MRC grant
Amount £60,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2010 
End 02/2013
 
Description MRC grant
Amount £16,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2012 
End 06/2013
 
Description MRC grant
Amount £10,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC grant
Amount £342,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC grant
Amount £24,500 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2010 
End 03/2013
 
Description MRC new investigator
Amount £160,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2012 
End 06/2013
 
Description MRC programme grant
Amount £2,100,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC programme grant
Amount £3,645,239 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC-PHE Centre for Environment & Health - 2014 Renewal -FK
Amount £404,243 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2014 
End 05/2019
 
Description MRC/ABPI
Amount £700,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description MRC/Technology Strategy Board
Amount £1,365,356 (GBP)
Funding ID MR/M025330/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2015 
End 06/2018
 
Description MRc grant
Amount £202,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2011 
End 05/2014
 
Description Modification of the host lipidome by Rhinovirus infection -RS
Amount £568,547 (GBP)
Funding ID MR/M004821/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2014 
End 09/2017
 
Description Modulation of redox-based airway remodelling in COPD through lysine acetylation and BET bromodomains
Amount £147,447 (GBP)
Funding ID R368/0714 
Organisation The Dunhill Medical Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2014 
End 10/2016
 
Description Modulation of redox-based airway remodelling in COPD through lysine acetylation and BET bromodomains - FCH
Amount £175,000 (GBP)
Funding ID R368/0714 
Organisation The Dunhill Medical Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Moulton Charitable Foundation
Amount £241,047 (GBP)
Organisation J P Moulton Charitable Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2011 
End 03/2013
 
Description MyAirCoach: Analysis, modelling and sensing of both physiological and environmental factors for the customized and predictive self-management of Asthma.
Amount £3,645,500 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start  
 
Description NE/H00324X/1 Clean air for London £3m across 11 participants (Kings component shared between T Lee and P Elliott)
Amount £450,000 (GBP)
Funding ID NE/H003231/1 
Organisation Natural Environment Research Council 
Sector Public
Country United Kingdom
Start 01/2010 
End 12/2012
 
Description NE/H012893/1 Risk Assessment for Manufactured Nanoparticles Used in Consumer Products (RAMNUC) (£1.4m shared between T Lee, P Elliott and T Tetley
Amount £384,244 (GBP)
Funding ID NE/H012893/1 
Organisation Natural Environment Research Council 
Sector Public
Country United Kingdom
Start 01/2011 
End 01/2015
 
Description NERC/MRC
Amount £1,000,000 (GBP)
Organisation Natural Environment Research Council 
Sector Public
Country United Kingdom
Start 01/2011 
End 12/2014
 
Description NERC/MRC
Amount £1,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2011 
End 12/2014
 
Description NH and MRC grant
Amount £374,554 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2010 
End 01/2013
 
Description NIAID - Immune Tolerance Network
Amount £1,154,721 (GBP)
Organisation National Institute of Allergy and Infectious Diseases (NIAID) 
Sector Public
Country United States
Start 02/2016 
End 01/2019
 
Description NIAID grant
Amount £8,713 (GBP)
Organisation National Institute of Allergy and Infectious Diseases (NIAID) 
Sector Public
Country United States
Start  
 
Description NIAID grant
Amount £33,327 (GBP)
Organisation National Institute of Allergy and Infectious Diseases (NIAID) 
Sector Public
Country United States
Start  
 
Description NIAID grant
Amount $1,071,117 (USD)
Organisation National Institute of Allergy and Infectious Diseases (NIAID) 
Sector Public
Country United States
Start  
 
Description NIH
Amount £791,300 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 02/2010 
End 12/2013
 
Description NIH Ancillary Award
Amount $1,255,925 (USD)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 02/2010 
End 12/2014
 
Description NIHR
Amount £1,900,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2012 
End 01/2017
 
Description NIHR BRC
Amount £75,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 07/2010 
End 06/2013
 
Description NIHR BRC
Amount £35,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 08/2010 
End 07/2011
 
Description NIHR BRC
Amount £280,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 07/2010 
End 06/2012
 
Description NIHR Senior Investigators: Seventh Annual Round (2013)
Amount £75,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2014 
End 03/2019
 
Description NIHR and BRC gluster grant
Amount £5,000,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Imperial Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start  
 
Description NIHR grant
Amount £1,000,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description NIHR senior
Amount £45,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 06/2012 
End 07/2014
 
Description National Institutes of Health (USA)
Amount £266,000 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 09/2011 
End 01/2015
 
Description National Institutes of Health (USA)
Amount £172,434 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 08/2011 
End 07/2015
 
Description New investigator research grant
Amount £500,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2010 
End 01/2013
 
Description Oates Salary NIHR - AB
Amount £22,800 (GBP)
Organisation Royal Brompton & Harefield NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 03/2013 
End 06/2013
 
Description POC grant: PKD inhibitors to treat rhinovirus infection - RS
Amount £18,000 (GBP)
Organisation Imperial Innovations 
Sector Private
Country United Kingdom
Start 11/2014 
End 10/2015
 
Description PREDICTA Post-infectious immune reprogramming and its association with persistence and chronicity of respiratory allergic diseases (6m euros across 13 participants)
Amount £377,932 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 10/2010 
End 09/2015
 
Description Pfizer grant
Amount £2,400,000 (GBP)
Organisation Pfizer Ltd 
Sector Private
Country United Kingdom
Start  
 
Description PhD extension funding - MB
Amount £36,758 (GBP)
Organisation Imperial College London 
Department Imperial College Trust
Sector Charity/Non Profit
Country United Kingdom
Start 10/2012 
End 09/2015
 
Description Pilot study: The use of respiratory muscle EMG as a predictor of extubation outcome in mechanically ventilated children-AG
Amount £56,099 (GBP)
Organisation Guy’s & St Thomas’ Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2013 
End 09/2014
 
Description Platform foR European Preparedness Against (Re)-emerging Epidemics (PREPARE) - po
Amount £1,347,243 (GBP)
Organisation European Commission 
Department Seventh Framework Programme (FP7)
Sector Public
Country European Union (EU)
Start 02/2014 
End 01/2019
 
Description Porgramme Grant - Wellcome Trust
Amount £975,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2011 
End 06/2016
 
Description Prevention of chronic respiratory morbidity in childhood - AG
Amount £213,080 (GBP)
Organisation Hungarian Academy of Sciences (MTA) 
Department Biological Research Centre (BRC)
Sector Academic/University
Country Hungary
Start 10/2014 
End 10/2017
 
Description Programme Grant - MRC
Amount £749,995 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2010 
End 03/2013
 
Description Programme Grant - MRC / ABPI
Amount £600,000 (GBP)
Organisation Association of the British Pharmaceutical Industry 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2016
 
Description Programme Grant - MRC / ABPI
Amount £560,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2011 
End 09/2016
 
Description Programme Grant - MRC / WT
Amount £500,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2011 
End 07/2013
 
Description Programme Grant - MRC / WT
Amount £500,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2011 
End 07/2013
 
Description Programme Grant - Medical Research Council/National Institute for Health Research (NIHR)
Amount £592,118 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description Programme Grant - Medical Research Council/National Institute for Health Research (NIHR)
Amount £500,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description Programme Grant - Wellcome Trust
Amount £457,611 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2010 
End 05/2014
 
Description Programme grant - MRC
Amount £1,840,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2011 
End 12/2016
 
Description Project Grant
Amount £420,000 (GBP)
Organisation Boehringer Ingelheim 
Sector Private
Country Germany
Start  
 
Description Project Grant - Asthma UK
Amount £49,600 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2011 
End 03/2012
 
Description Project Grant - Asthma UK
Amount £42,878 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2010 
End 07/2011
 
Description Project Grant - Asthma UK
Amount £49,500 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2010 
End 09/2011
 
Description Project Grant - BBSRC
Amount £458,250 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2010 
End 12/2013
 
Description Project Grant - GSK
Amount £94,196 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 11/2009 
End 10/2010
 
Description Project Grant - MRC
Amount £857,612 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2011 
End 05/2014
 
Description Project Grant - MRC
Amount £274,028 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2012 
End 03/2014
 
Description Project Grant - WT
Amount £368,312 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2010 
End 10/2013
 
Description R Snelgrove - Substrate-selective inhibition of LTA4H for the treatment of neutrophilic asthma
Amount £98,221 (GBP)
Organisation Apollo Therapeutics 
Sector Private
Country United Kingdom
Start 03/2017 
End 11/2017
 
Description R Snelgrove - Therapeutic potential of Coversin in a mouse model of allergic airways disease
Amount £122,818 (GBP)
Organisation Akari Therapeutics 
Start 01/2017 
End 02/2018
 
Description RMN - Gradient Station for Frac-seq in asthma
Amount £10,000 (GBP)
Organisation King’s Health Partners 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 09/2018
 
Description Regulation of interferon production in the lung during respiratory syncytial virus infection.
Amount £1,337,305 (GBP)
Funding ID G0800311 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2007 
End 06/2015
 
Description Research Fellowship
Amount £162,161 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2012 
End 10/2014
 
Description Research excelence award
Amount £150,000 (GBP)
Organisation Imperial College London 
Sector Academic/University
Country United Kingdom
Start 01/2010 
End 01/2012
 
Description Respiratory Infection Health Protection Research Unit -PO
Amount £3,427,262 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2014 
End 03/2019
 
Description Respiratory Infection Health Protection Unit (HPRU)
Amount £3,427,262 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2013 
End 03/2019
 
Description Respiratory Pharmacology Staff - MB
Amount £83,213 (GBP)
Organisation Imperial College London 
Department Imperial College Trust
Sector Charity/Non Profit
Country United Kingdom
Start 01/2012 
End 09/2015
 
Description Rosetrees Trust Award
Amount £19,924 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2016 
End 10/2017
 
Description Royal Brompton & Harefield NHS Trust
Amount £13,600 (GBP)
Organisation Royal Brompton & Harefield NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 10/2010 
End 03/2011
 
Description SD - Defining best Management for Adults with Chronic RhinOsinusitis: the MACRO Programme
Amount £10,688 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 06/2017 
End 06/2023
 
Description SD - EECCAT mechanistic
Amount £297,913 (GBP)
Organisation Benaroya Research Institute at Virginia Mason (BRI) 
Sector Academic/University
Country United States
Start 02/2017 
End 01/2018
 
Description SD - Induction of human allergen-specific immune regulation following treatment with a combination of Toll-Like Receptor 7 Agonist with allergen: an in vitro proof
Amount £151,094 (GBP)
Funding ID MR/R502170/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2018 
End 12/2018
 
Description SD - Pre-clinical food allergy program
Amount £1,740,707 (GBP)
Organisation Asit Biotech SA 
Start 04/2017 
End 04/2019
 
Description SS - Manipulating asthma susceptibility genes and environmental exposures to work out what causes wheezing in preschool children and find treatments to prevent development of asthma
Amount £22,500 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description ST - Role of Eosinophils and Basophils in Chronic Spontaneous (Idiopathic) Urticaria.
Amount £17,800 (GBP)
Organisation TC Ltd 
Sector Private
Country United Kingdom
Start 01/2017 
End 09/2019
 
Description SW52ZXN0aWdhdGluZyB0aGUgaW1wYWN0IG9mIExvbmRvbsOiwoDCmXMgVWx0cmEgTG93IEVtaXNz aW9uIFpvbmUgb24gY2hpbGRyZW7DosKAwplzIHJlc3BpcmF0b3J5IGhlYWx0aA==
Amount £2,573,442 (GBP)
Funding ID PHR/16/139/01 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2018 
End 12/2023
 
Description Senior Research Fellowship
Amount £1,667,327 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2018 
End 03/2023
 
Description Single-cell analysis of the local nasal B cell response to allergen immunotherapy - HG
Amount £49,881 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2014 
End 10/2015
 
Description Stallergenes
Amount £44,552 (GBP)
Organisation Stallergenes Group 
Sector Private
Country Global
Start 01/2011 
End 09/2011
 
Description Strategic Environmental Science Capital Call - FK
Amount £300,000 (GBP)
Organisation Natural Environment Research Council 
Sector Public
Country United Kingdom
Start 01/2014 
End 06/2014
 
Description Structural studies to advance understanding of IgM and its complement and receptor interactions - BS
Amount £468,367 (GBP)
Funding ID BB/K006142/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 11/2012 
End 10/2015
 
Description Structure, function & regulation of IgE - HG
Amount £331,890 (GBP)
Organisation Hungarian Academy of Sciences (MTA) 
Department Biological Research Centre (BRC)
Sector Academic/University
Country Hungary
Start 04/2012 
End 03/2017
 
Description Subproject for Institution # P42422 -ABu
Amount £34,997 (GBP)
Organisation Royal Brompton & Harefield NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 04/2012 
End 03/2017
 
Description Systems Immunology of the human Life Course Award-SJ
Amount £2,235,278 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2014 
End 05/2019
 
Description The Asthma UK Centre Allergy Mechanisms in Asthma
Amount £953,495 (GBP)
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2016 
End 08/2021
 
Description The Asthma UK Centre in Mechanisms of Asthma
Amount £1,999,074 (GBP)
Funding ID AUK-BC-2015-01 
Organisation Asthma UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2016 
End 08/2021
 
Description The Consequences of Neonatal Respiratory Virus Infection for Pulmonary Innate Immunity -po
Amount £5,000,344 (GBP)
Funding ID G1001763 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2011 
End 12/2014
 
Description The Freemasons' Grand Charity
Amount £400,000 (GBP)
Organisation The Freemasons' Grand Charity 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2009 
End 01/2013
 
Description The London Metallomics Facility
Amount £390,000 (GBP)
Funding ID 202902/Z/16/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 09/2021
 
Description The SLIC study - overcoming ethnic differences: a 3D approach to body physique for predicting lung function in children. - FK
Amount £5,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2013 
End 01/2014
 
Description The immunomodulatory effects of WF10 on grass pollen specific T cells, B cell and basophil responses - SD
Amount £200,000 (GBP)
Organisation Nuovo Parts 
Sector Private
Country United States
Start 11/2014 
End 10/2015
 
Description The molecular and cellular basis of complement-mediated T helper 1 (TH1) differentation and regulation - PL
Amount £876,000 (GBP)
Funding ID G1002165 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2011 
End 02/2014
 
Description The role of Bromodomain-containing proteins in pulmonary arterial hypertension - IA
Amount £295,177 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2014 
End 09/2017
 
Description The role of IgE antibodies in non-atopic asthma
Amount £360,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description The role of bromodomain-containing protein in vascular cell inflammation and proliferation in pulmonary hypertension
Amount £292,177 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Translational development of early stage drug development projects
Amount £519,000 (GBP)
Organisation Apollo Therapeutics 
Sector Private
Country United Kingdom
Start 04/2017 
End 09/2017
 
Description UCB Industrial Collaboration
Amount £156,718 (GBP)
Organisation UCB Pharma 
Sector Private
Country United Kingdom
Start 01/2016 
End 12/2016
 
Description UCB Pharma
Amount £174,000 (GBP)
Organisation UCB Pharma 
Sector Private
Country United Kingdom
Start 01/2017 
End 01/2018
 
Description UCB Pharma
Amount £120,000 (GBP)
Organisation UCB Pharma 
Sector Private
Country United Kingdom
Start 02/2017 
End 02/2018
 
Description UCB Pharma/EU/IMI project grant
Amount £340,000 (GBP)
Organisation UCB Pharma 
Sector Private
Country United Kingdom
Start 01/2012 
End 01/2015
 
Description UK Cystic Fibrosis Trust
Amount £72,096 (GBP)
Organisation Cystic Fibrosis Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description UK Cystic Fibrosis Trust
Amount £146,732 (GBP)
Organisation Cystic Fibrosis Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2012 
End 10/2014
 
Description Uncoupling harmful pro-inflamatory cytokine responses from beneficial anti-viral immunity - SJ
Amount £63,340 (GBP)
Organisation Hungarian Academy of Sciences (MTA) 
Department Biological Research Centre (BRC)
Sector Academic/University
Country Hungary
Start 12/2013 
End 05/2014
 
Description Understanding neonatal immune responses to respiratory syncytial virus (RSV) and determining potential targets for vaccines
Amount £57,000 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2013 
End 09/2016
 
Description United Kingdom Oscillation Study: Long-term outcomes at follow up of two modes of neonatal ventilation - AG
Amount £665,711 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 10/2010 
End 09/2014
 
Description United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
Amount £4,761,430 (GBP)
Funding ID MR/M016579/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2015 
End 04/2019
 
Description University of Leicester
Amount £10,699 (GBP)
Organisation University of Leicester 
Sector Academic/University
Country United Kingdom
Start 03/2011 
End 02/2016
 
Description University of Leicester - project grant
Amount £39,619 (GBP)
Organisation University of Leicester 
Sector Academic/University
Country United Kingdom
Start 03/2011 
End 02/2016
 
Description Unrestricted research grant from Novartis Pharmaceuticals
Amount £280,000 (GBP)
Organisation Novartis 
Sector Private
Country Global
Start  
 
Description Upper and lower airway mucosal immunology in respiratory diseases - PO
Amount £200,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2014 
End 03/2016
 
Description Use of molecular profiling to determine optimal management for moderate to severe preschool wheeze
Amount £770,611 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 01/2015 
End 12/2018
 
Description WT - BC/MM
Amount £3,183,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 08/2018
 
Description WT grant
Amount £45,659 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description WT grant
Amount £251,635 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2011 
End 01/2014
 
Description WT/NIH grant
Amount £70,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2014
 
Description Wellcome Foundation Clinical Research Fellowship
Amount £250,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2014
 
Description Wellcome Trust
Amount £975,642 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2011 
End 06/2016
 
Description Wellcome Trust Translational Fund
Amount £2,550,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2018
 
Description Wellcome trust
Amount £248,744 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2011 
End 08/2014
 
Description brc grant
Amount £119,196 (GBP)
Organisation National Institute for Health Research 
Department NIHR Imperial Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 01/2012 
End 01/2014
 
Description dainippon-sumitomo pharma - grant
Amount £640,000 (GBP)
Organisation Sumitomo Corporation 
Department Dainippon Sumitomo Pharma Co
Sector Private
Country Japan
Start 03/2012 
End 03/2014
 
Description nihr senior - SJ
Amount £60,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 06/2009 
End 07/2014
 
Title Basophil activation test 
Description The whole blood basophil activation test is an in vitro assay where basophils in whole blood are stimulated with allergen and the expression of basophils' surface markers of activation are subsequently measured by flow cytometry. This assay was not previously performed in the host institution, was developed and optimised as part of the present research project and has proven to be very robust and to perform consistently. 
Type Of Material Technology assay or reagent 
Year Produced 2013 
Provided To Others? Yes  
Impact The basophil activation test (BAT) will be assessed as a tool for the diagnosis of food allergy and will be used in mechanistic experiments. BAT will be clinically validated and may be applied in the diagnosis of food allergy in clinical practice, reducing the need for oral food challenges and inherent costs and risks. BAT will also be used to unravel immunologic mechanisms of allergy versus tolerance, allowing us to understand why some children with IgE to foods react clinically whilst other children with equivalent levels of IgE do not. 
 
Title Cohort 
Description Establishment of an extremely prematurely born cohort who were recruited into an MRC funded randomised trial. Establishment of an extremely prematurely born cohort with all respiratory viral infections characterised in the first two years of life and detailed lung function measurements. 
Type Of Material Physiological assessment or outcome measure 
Provided To Others? No  
Impact We have demonstrated that one neonatal mode of ventilation was associated with superior outcome in adolescence. Prematurely born infants were functionally and genetically predisposed to respiratory viral infections which further impaired their lung function. 
 
Title Ex vivo CaSR studies 
Description Ex vivo lung segment analysis of smooth muscle hyperresponsiveness in collaboration with the physiologists at the University of Cardiff (Riccardi/Kemp) 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Provided To Others? No  
Impact Demonstration that CaSR k/o mice lose hyperactivity to polycationic agonists such as eosinophil cationic protein 
 
Title Ex vivo prostanoid production 
Description sSyetm for direct, ex vivo culture of resected nasal polyps from patients with aspirin sensitive rhinosinusitis to study eicoasoind metablism and its regulation by drugs such as COX-1 inhibitors usinmg cell proportions directly exe vivo 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2006 
Provided To Others? Yes  
Impact None as yet 
 
Title ISAC 
Description In house allergen compoent resolved diagnosis (ISAC) facility 
Type Of Material Technology assay or reagent 
Year Produced 2012 
Provided To Others? Yes  
Impact Analysis of the IgE repertoire in biological samples such as bronchial biopsies 
 
Title IgE autoantibody ELISA 
Description Elisa for detevtion of human IgG aotoantibodies against IgE or the high-affinity IgE-receptor FceRI. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Rapid screeeing tool for subset of non-atopic asthmartics expressing such antibodies. 
 
Title Mast cell activation and inhibition assays 
Description The mast cell activation assay is a flow-cytomety based assay where mast cells from a cell line are sensitised with patients' plasma and stimulated with allergens or controls. It is an in vitro surrogate of provocation tests where patients are exposed to the allergens in vivo. The inhibition assay is similar, where the mast cells are in the presence of plasma samples that are tested for their ability to suppress mast cell activation. It can be used as a marker for clinical improvement of allergic disease. 
Type Of Material Technology assay or reagent 
Year Produced 2015 
Provided To Others? Yes  
Impact MAT can be used to diagnose food allergy and as a biomarker for clinical improvement in clinical trials testing preventive or therapeutic strategies for food allergy. 
 
Title Primary bronchial epithelial cell culture from asthmatic brushings 
Description Growing bronchial epithelial cells from bronchial brushings. 
Type Of Material Biological samples 
Year Produced 2011 
Provided To Others? Yes  
Impact Allows experimentation of primary cells and useful in academic research and drug discovery. 
 
Title Real time tracking 
Description Labelling of neutrophils and eosinophils ex vivo for separate injection and tracking of net influx/efflux from organs such as the lung in asthmatics in real time. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2014 
Provided To Others? Yes  
Impact None as yet since just developed but should be useful in phenotyping asthma and other diseases and examining the effects of new therapeutic agents. 
 
Title Selective LTA4H modulators 
Description I have undertaken a drug development program to develop selective LTA4H inhibitors that will abrogate the pro-inflammatory LTB4-generating activity but preserve the anti-inflammatory PGP-degrading activity of the enzyme. We have successfully identified two chemical series that can distinguish between activities, which have been further developed through Asthma UK funding, and that we anticipate to be the starting point for superior, selective drugs to target LTA4H. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact We are hopeful that our selective LTA4H modulators will be developed into drugs for targeting LTB4 in an array of disease modalities. 
 
Title LEAP Study Database 
Description The data collected as part of the LEAP Study has been made public as it is being published. 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact Other researchers have been able to analyse the data themselves using Trialshare. 
URL https://www.itntrialshare.org/
 
Description AB - Vit D 
Organisation King's College London
Department School of Medicine KCL
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration betweenDr Saglani and Profs Bush, Lloyd and Hawrylowicz to study the role of Vitamin D in paediatric severe therapy resistant asthma.
Collaborator Contribution knowledge sharing
Impact Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, Saglani S. Relationship Between Serum Vitamin D, Disease Severity and Airway Remodeling in Children with Asthma. Am. J. Respir. Crit. Care Med., Sep 2011; doi:10.1164/rccm.201107-1239OC. More publications submitted, and a new, centre-funded PhD project has been initiated in consequence
Start Year 2011
 
Description AN - Johnson & Johnson 
Organisation Johnson & Johnson
Country United States 
Sector Private 
PI Contribution Proof-of concept funding for collaborative pilot project on regulatory T cell function
Collaborator Contribution Proof-of concept funding for collaborative pilot project on regulatory T cell function
Impact Proof-of concept funding for collaborative pilot project on regulatory T cell function
Start Year 2012
 
Description Airway smooth muscle culture from bronchial biopsies 
Organisation King's College London
Department Department of Physiology
Country United Kingdom 
Sector Academic/University 
PI Contribution Setting the method for in vitro culture of human airway smooth muscle from bronchial biopsies
Collaborator Contribution Selection of patients, performing bronchoscopies and collecting biopsies. Culture of human airway smooth muscle
Impact Setting up a unique model to study human airways. Research projects in progress.
Start Year 2009
 
Description Airway smooth muscle culture from bronchial biopsies 
Organisation King's College London
Department Department of Respiratory Medicine and Allergy
Country United Kingdom 
Sector Academic/University 
PI Contribution Setting the method for in vitro culture of human airway smooth muscle from bronchial biopsies
Collaborator Contribution Selection of patients, performing bronchoscopies and collecting biopsies. Culture of human airway smooth muscle
Impact Setting up a unique model to study human airways. Research projects in progress.
Start Year 2009
 
Description Associate Prof Fred Wong 
Organisation National University of Singapore
Country Singapore 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Asthma UK Centre for Allergic Mechanisms of Asthma 
Organisation Asthma UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution A collaboration of Asthma UK with King's and Imperial Colleges in the University of London to provide a forum for research collaboration and training in asthma.
Collaborator Contribution Funding, mutual consultation on research priorities and protocols, supply of research subjects, training of clinical and non-clinical PhD students.
Impact Om going research for the benefit of asthma sufferers.
Start Year 2015
 
Description AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Anti-ICAM approaches in RV infections.
Collaborator Contribution Anti-ICAM approaches in RV infections.
Impact ....
Start Year 2009
 
Description AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution The effect of CCR3 antagonism on RSV transmissibility.
Collaborator Contribution The effect of CCR3 antagonism on RSV transmissibility.
Impact ...
Start Year 2006
 
Description AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Characterising the molecular defect in interferon production in asthma.
Collaborator Contribution Characterising the molecular defect in interferon production in asthma.
Impact ....
 
Description AstraZeneca Open Innovation 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution We have tested the AstraZeneca MMP-12 inhibitor, AZD1236, in our murine models of allergic airways disease.
Collaborator Contribution The AstraZeneca Open Innovation scheme has provided the MMP-12 inhibitor AZD1236 to assess in our murine models of allergic airways disease.
Impact Still pending
Start Year 2017
 
Description Auto-anti-IgE project 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution I contributed with intellectual input into the project regarding basophil experiments and also performed some experiments as part of this collaboration.
Collaborator Contribution Professor Corrigan and his team recruited asthmatic and non-asthmatic subjects to the study and Professor Gould and her team performed experiments to detec the presence of anti-IgE and anti-FceRI and other auto antibodies in the serum of asthmatic and non-asthmatic subjects.
Impact Publication PMID: 25112697
Start Year 2011
 
Description Basophil activation test in the LEAP and LEAP-On studies 
Organisation National Institute of Allergy and Infectious Diseases (NIAID)
Country United States 
Sector Public 
PI Contribution Following successful development of basophil activation test to peanut, we have started to apply this technique to participants in the LEAP and LEAP-On studies.
Collaborator Contribution The NIAID and the Immune Tolerance Network are funding and monitoring the LEAP and LEAP-On trials.
Impact Publications are planned but for the time being we are still blinded for the
Start Year 2011
 
Description Basophil activation test in the PRONUTS Study 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution I have been performing the basophil activation test in participants in the Pronuts Study at the London site.
Collaborator Contribution This is a multicentre study, including the 3 centres indicated above. All centres have been recruiting study participants. At KCL, I collaborate with Dr Helen Brough (PI) and Professor Gideon Lack (CI).
Impact No outputs yet as the collaboration is ongoing and data will only be analysed at the end of the study.
Start Year 2013
 
Description Basophil activation test in the PRONUTS Study 
Organisation University of Geneva
Country Switzerland 
Sector Academic/University 
PI Contribution I have been performing the basophil activation test in participants in the Pronuts Study at the London site.
Collaborator Contribution This is a multicentre study, including the 3 centres indicated above. All centres have been recruiting study participants. At KCL, I collaborate with Dr Helen Brough (PI) and Professor Gideon Lack (CI).
Impact No outputs yet as the collaboration is ongoing and data will only be analysed at the end of the study.
Start Year 2013
 
Description Basophil activation test in the PRONUTS Study 
Organisation University of Valencia
Country Spain 
Sector Academic/University 
PI Contribution I have been performing the basophil activation test in participants in the Pronuts Study at the London site.
Collaborator Contribution This is a multicentre study, including the 3 centres indicated above. All centres have been recruiting study participants. At KCL, I collaborate with Dr Helen Brough (PI) and Professor Gideon Lack (CI).
Impact No outputs yet as the collaboration is ongoing and data will only be analysed at the end of the study.
Start Year 2013
 
Description Calcilytics for asthma 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Human studies on smooth muscle calcium sensing receptor expression in asthma
Collaborator Contribution In vitro studies and animal models
Impact Patent application Formation of new company (Numedicus)
Start Year 2012
 
Description Cationic proteins 
Organisation Cardiff University
Department School of Biosciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Measured expression of cationic proteins in human asthmatic tissue sections
Collaborator Contribution Measured effects of cationic proteins on reactivity and calcium flux of human airways smooth muscle
Impact MRC project grant application
Start Year 2012
 
Description Centocor, USA 
Organisation Janssen Biotech, Inc.
Country United States 
Sector Private 
PI Contribution Discovery of novel therapies for asthma exacerbations.
Collaborator Contribution Discovery of novel therapies for asthma exacerbations.
Impact ....
 
Description Collaboration with Professor Andrew Menzies-Gow of Imperial College / Royal Brompton Hospital to acquire clinical samples. 
Organisation Royal Brompton Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution As part of my Wellcome Trust Senior Fellowship I acquired funding for the acquisition of samples from severe asthmatics and healthy controls. Within these samples my group will extensively characterize the specific pathways in order to understand why it is aberrant and the patient groups most likely to benefit from our therapeutics.
Collaborator Contribution Professor Menzies-Gow is a clinical scientist who has/ will be instrumental in acquiring ethics, patient consent and ultimately clinical samples as well as intellectual input into the clinical relevance of our results.
Impact Collaboration just initiated and awaiting approval of ethics.
Start Year 2019
 
Description DF - Stephen Devereux 
Organisation University of Sussex
Country United Kingdom 
Sector Academic/University 
PI Contribution collaboration
Collaborator Contribution collaboratioan
Impact Manuscript in preparation
Start Year 2011
 
Description Differential production and regulation of IL-17 in steroid sensitive and refractory asthma 
Organisation King's College London
Department Department of Respiratory Medicine and Allergy
Country United Kingdom 
Sector Academic/University 
PI Contribution Immunogical analyses to investigate differential production and regulation of IL-17 in well characterized steroid sensitive and refractory asthma
Collaborator Contribution Clinical responsibility for patient characterization, contribution to study design
Impact Paper submitted and in revision
Start Year 2011
 
Description Does reduced production of IL-10 predict steroid refractoriness in children with severe asthma? 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Immunological analyses in severe therapy refractory pediatric asthmatics: impact vitamin D status
Collaborator Contribution Recruitment clincially characterized patient cohort, and collaboration on study deisign
Impact Vitamin D and asthma in children. Gupta A, Bush A, Hawrylowicz C, Saglani S. Paediatr Respir Rev. 2012 Dec;13(4):236-43; quiz 243. doi: 10.1016/j.prrv.2011.07.003. Epub 2011 Sep 1. PMID: 23069123 The role of 1a,25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Urry Z, Chambers ES, Xystrakis E, Dimeloe S, Richards DF, Gabryšová L, Christensen J, Gupta A, Saglani S, Bush A, O'Garra A, Brown Z, Hawrylowicz CM. Eur J Immunol. 2012 Oct;42(10):2697-708. doi: 10.1002/eji.201242370. Epub 2012 Aug 20. PMID: 22903229 [PubMed - indexed for MEDLINE] Free PMC Article Vitamin D binding protein and asthma severity in children. Gupta A, Dimeloe S, Richards DF, Bush A, Saglani S, Hawrylowicz CM. J Allergy Clin Immunol. 2012 Jun;129(6):1669-71. doi: 10.1016/j.jaci.2012.02.017. Epub 2012 Mar 28. No abstract available. PMID: 22460073 [PubMed - indexed for MEDLINE] 1a,25-dihydroxyvitamin D3 promotes CD200 expression by human peripheral and airway-resident T cells. Dimeloe S, Richards DF, Urry ZL, Gupta A, Stratigou V, Farooque S, Saglani S, Bush A, Hawrylowicz CM. Thorax. 2012 Jul;67(7):574-81. doi: 10.1136/thoraxjnl-2011-200651. Epub 2012 Feb 14. PMID: 22334534 [PubMed - indexed for MEDLINE] Free PMC Article Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, Saglani S. Am J Respir Crit Care Med. 2011 Dec 15;184(12):1342-9. doi: 10.1164/rccm.201107-1239OC. Epub 2011 Sep 8. PMID: 21908411 [PubMed - indexed for MEDLINE] Free PMC Article
Start Year 2009
 
Description Dr Andrew McKenzie 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Dr Axel Nohturfft, University of London 
Organisation St George's University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Dr Caroline Low - Medicinal chemistry expertise for development of novel LTA4H modulators 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution I have undertaken a drug development program to develop selective LTA4H inhibitors that will abrogate the pro-inflammatory LTB4-generating activity but preserve the anti-inflammatory PGP-degrading activity of the enzyme. My research team have been integral in the design and testing of these novel inhibitors.
Collaborator Contribution Caroline Low possesses extensive expertise in molecular modelling and computational drug discovery. I have worked with her for the last 5 years to develop novel LTA4H inhibitors, initially in her capacity as a member of the Drug Discovery Centre at Imperial College and more recently as a consultant - although she has committed many more hours to this project than for which she has received recompense. More recently, throughout the Asthma UK award Caroline has independently offered advice on drug profiles and liaised with Peakdale on the synthesis of compounds- all without receiving payment in an effort to develop these compounds to viable therapeutic targets.
Impact Working with Caroline has enabled me to secure four independent grant awards to develop and test our novel LTA4H modulators: 1. Biomedical Research Centre /Imperial Innovations funding for award entitled "Manipulating the dual functions of LTA4H" (08.2012-02.2013; £22,200). 2. Medical Research Council / Imperial Innovations for award entitled "Manipulating the dual functions of LTA4H: one drug to target two pro-inflammatory mediators tightly implicated in neutrophilic lung disease" (08.2013-04.2014; £56,075). 3. Medical Research Council / Imperial Innovations for award entitled "Manipulating the dual functions of LTA4H: one drug to target two pro-inflammatory mediators - Proof of concept in neutrophilic lung disease models"(06.2014-09.2014; £30,744). 4. Asthma UK Innovations award entitled "The development of superior LTA4H modulators for treatment of allergic airway disease"(10.2014-03.2016; £46,540) During the Asthma UK award, her input and industrial expertise has been invaluable in evaluating drug profiles and directing drug synthesis. This has ultimately led to a successful project for which we are currently preparing two manuscripts.
Start Year 2011
 
Description Dr David Cousins 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Dr Hans Bisgaard 
Organisation University of Copenhagen
Department Danish Paediatric Asthma Centre
Country Denmark 
Sector Multiple 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Dr Stephen Hare (Department of Chemistry, ICL): X-ray crystallography of novel LTA4H modulators 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution I have undertaken a drug development program to develop selective LTA4H inhibitors that will abrogate the pro-inflammatory LTB4-generating activity but preserve the anti-inflammatory PGP-degrading activity of the enzyme. My research team have been integral in the design and testing of these novel inhibitors.
Collaborator Contribution Dr Stephen Hare of Imperial College has performed X-ray crystallography studies of our lead compounds within the active site of LTA4H, validating our molecular modelling and rationalizing the selective inhibition seen with our compounds in our in-house assays.
Impact Successful structures have been elucidated and form part of a manuscript currently in preparation. An understanding of the mechanism of action of our novel compounds is important if we are to use them, or their derivatives, as future drugs for the treatment of asthma and other diseases.
Start Year 2015
 
Description Drs Scott Weiss, Augusto Litonjua, George O'Connor 
Organisation Harvard University
Department Channing Laboratory
Country United States 
Sector Academic/University 
PI Contribution Investigation of the impact of vitamin D in pregnancy on immunity of the neonate
Collaborator Contribution Running a clinical trial of vitamin D supplementation in pregnancy, supporting intellectually and through sample provision immune studies of impact vitamin D on neonatal immunity.
Impact Lange NE, Litonjua A, Hawrylowicz CM, Weiss S. Vitamin D, the immune system and asthma. Expert Rev Clin Immunol. 2009 Nov;5(6):693-702. Lange NE, Zhou X, Lasky-Su J, Himes BE, Lazarus R, Soto-Quirós M, Avila L, Celedón JC, Hawrylowicz CM, Raby BA, Litonjua AA. Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma-related phenotypes. BMC Med Genet. 2011 Feb 15;12:26. doi: 10.1186/1471-2350-12-26. Litonjua AA, Carey VJ, Laranjo N, Harshfield BJ, McElrath TF, O'Connor GT, Sandel M, Iverson RE Jr, Lee-Paritz A, Strunk RC, Bacharier LB, Macones GA, Zeiger RS, Schatz M, Hollis BW, Hornsby E, Hawrylowicz C, Wu AC, Weiss ST. Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. JAMA. 2016 Jan 26;315(4):362-70. doi: 10.1001/jama.2015.18589.
Start Year 2009
 
Description Epitope IgE and IgG4 testing 
Organisation Benaroya Research Institute at Virginia Mason (BRI)
Country United States 
Sector Academic/University 
PI Contribution 1. We recruited patients who were being assessed for peanut allergy and designed the study in which we were assessing the hypothesis that differences in peanut epitope binding could explain differences in clinical reactivity (i.e. being allergic or not allergic) in children that had IgE to peanut. 2. We made contact with collaborators in New Orleans who tested IgE and IgG4 binding on a microarray containing peptides from all peanut allergens described to date. 3. We designed the analyses plan together with a computational biologist based in Oxford and Lisbon (now only in Lisbon) who performed the analyses of the microarray data. 4. We designed and performed functional assays to validate the findings using cellular tests in my laboratory. 5. We established a collaboration with Thermofisher to couple the peptides to a solid phase using ImmunoCAP technology, which enabled us to validate the microarray findings with quantitative method that could be come accessible to the clinical community. We tested all the samples in our laboratory using this technology. 6. ImmunoCAP and microarray data were analysed by statisticians at the BRI.
Collaborator Contribution - Collaborators from Southern Regional Research Centre performed microarray experiments - Collaborators from University of Lisbon helped analysing the microarray data - Collaborators from Thermofisher scientific coupled the peptides to the solid phase using the peptides we provided and sent the material to our lab to use for testing. - Collaborators from Benaroya Research Institute analysed the ImmunoCAP data - Collaborators from Queen Mary University of London contributed in an advisory capacity
Impact Abstract for meeting has been accepted as oral presentation to be presented at the annual congress of the European Academy of Allergy and Clinical Immunology. The manuscript is currently being reviewed by the editorial board of the Journal of Allergy and Clinical Immunology.
Start Year 2011
 
Description Epitope IgE and IgG4 testing 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution 1. We recruited patients who were being assessed for peanut allergy and designed the study in which we were assessing the hypothesis that differences in peanut epitope binding could explain differences in clinical reactivity (i.e. being allergic or not allergic) in children that had IgE to peanut. 2. We made contact with collaborators in New Orleans who tested IgE and IgG4 binding on a microarray containing peptides from all peanut allergens described to date. 3. We designed the analyses plan together with a computational biologist based in Oxford and Lisbon (now only in Lisbon) who performed the analyses of the microarray data. 4. We designed and performed functional assays to validate the findings using cellular tests in my laboratory. 5. We established a collaboration with Thermofisher to couple the peptides to a solid phase using ImmunoCAP technology, which enabled us to validate the microarray findings with quantitative method that could be come accessible to the clinical community. We tested all the samples in our laboratory using this technology. 6. ImmunoCAP and microarray data were analysed by statisticians at the BRI.
Collaborator Contribution - Collaborators from Southern Regional Research Centre performed microarray experiments - Collaborators from University of Lisbon helped analysing the microarray data - Collaborators from Thermofisher scientific coupled the peptides to the solid phase using the peptides we provided and sent the material to our lab to use for testing. - Collaborators from Benaroya Research Institute analysed the ImmunoCAP data - Collaborators from Queen Mary University of London contributed in an advisory capacity
Impact Abstract for meeting has been accepted as oral presentation to be presented at the annual congress of the European Academy of Allergy and Clinical Immunology. The manuscript is currently being reviewed by the editorial board of the Journal of Allergy and Clinical Immunology.
Start Year 2011
 
Description Epitope IgE and IgG4 testing 
Organisation Thermo Fisher Scientific
Country United States 
Sector Private 
PI Contribution 1. We recruited patients who were being assessed for peanut allergy and designed the study in which we were assessing the hypothesis that differences in peanut epitope binding could explain differences in clinical reactivity (i.e. being allergic or not allergic) in children that had IgE to peanut. 2. We made contact with collaborators in New Orleans who tested IgE and IgG4 binding on a microarray containing peptides from all peanut allergens described to date. 3. We designed the analyses plan together with a computational biologist based in Oxford and Lisbon (now only in Lisbon) who performed the analyses of the microarray data. 4. We designed and performed functional assays to validate the findings using cellular tests in my laboratory. 5. We established a collaboration with Thermofisher to couple the peptides to a solid phase using ImmunoCAP technology, which enabled us to validate the microarray findings with quantitative method that could be come accessible to the clinical community. We tested all the samples in our laboratory using this technology. 6. ImmunoCAP and microarray data were analysed by statisticians at the BRI.
Collaborator Contribution - Collaborators from Southern Regional Research Centre performed microarray experiments - Collaborators from University of Lisbon helped analysing the microarray data - Collaborators from Thermofisher scientific coupled the peptides to the solid phase using the peptides we provided and sent the material to our lab to use for testing. - Collaborators from Benaroya Research Institute analysed the ImmunoCAP data - Collaborators from Queen Mary University of London contributed in an advisory capacity
Impact Abstract for meeting has been accepted as oral presentation to be presented at the annual congress of the European Academy of Allergy and Clinical Immunology. The manuscript is currently being reviewed by the editorial board of the Journal of Allergy and Clinical Immunology.
Start Year 2011
 
Description Epitope IgE and IgG4 testing 
Organisation University of Lisbon
Department Institute for Molecular Medicine
Country Portugal 
Sector Academic/University 
PI Contribution 1. We recruited patients who were being assessed for peanut allergy and designed the study in which we were assessing the hypothesis that differences in peanut epitope binding could explain differences in clinical reactivity (i.e. being allergic or not allergic) in children that had IgE to peanut. 2. We made contact with collaborators in New Orleans who tested IgE and IgG4 binding on a microarray containing peptides from all peanut allergens described to date. 3. We designed the analyses plan together with a computational biologist based in Oxford and Lisbon (now only in Lisbon) who performed the analyses of the microarray data. 4. We designed and performed functional assays to validate the findings using cellular tests in my laboratory. 5. We established a collaboration with Thermofisher to couple the peptides to a solid phase using ImmunoCAP technology, which enabled us to validate the microarray findings with quantitative method that could be come accessible to the clinical community. We tested all the samples in our laboratory using this technology. 6. ImmunoCAP and microarray data were analysed by statisticians at the BRI.
Collaborator Contribution - Collaborators from Southern Regional Research Centre performed microarray experiments - Collaborators from University of Lisbon helped analysing the microarray data - Collaborators from Thermofisher scientific coupled the peptides to the solid phase using the peptides we provided and sent the material to our lab to use for testing. - Collaborators from Benaroya Research Institute analysed the ImmunoCAP data - Collaborators from Queen Mary University of London contributed in an advisory capacity
Impact Abstract for meeting has been accepted as oral presentation to be presented at the annual congress of the European Academy of Allergy and Clinical Immunology. The manuscript is currently being reviewed by the editorial board of the Journal of Allergy and Clinical Immunology.
Start Year 2011
 
Description GPCR Imperial 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration on research on G-protein coupled receptors in immune responses. PMID: 22391114
Collaborator Contribution Collaboration on research on G-protein coupled receptors in immune responses. -Intelectual input -Access to facilities
Impact PMID: 22391114
Start Year 2010
 
Description GPCRs King's 
Organisation King's College London
Department Division of Asthma, Allergy and Lung Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration on several projects studying role of G-protein coupled receptors in asthma and allergy. PMID: 23472176; PMID: 22391114
Collaborator Contribution Collaboration on several projects studying role of G-protein coupled receptors in asthma and allergy. -Intellectual input -Access to facilities -Training of staff
Impact PMID: 23472176; PMID: 22391114
Start Year 2010
 
Description GW - Collaboration with Critical Care Medicine Department, National Health Institutes, USA (dr James Shelhamer) 
Organisation National Institutes of Health Clinical Center
Department Critical Care Medicine Department (CCMD)
Country United States 
Sector Hospitals 
PI Contribution Directly involved in project design, performing experiments, analysing data and writing manuscript.
Collaborator Contribution Directly involved in project design, performing experiments, analysing data and writing manuscript.
Impact Publication - Cooperative and redundant signaling of leukotriene B4 and leukotriene D4 in human monocytes. Chen LY, Eberlein M, Alsaaty S, Martinez-Anton A, Barb J, Munson PJ, Danner RL, Liu Y, Logun C, Shelhamer JH, Woszczek G. Allergy. 2011 Oct;66(10):1304-11. doi: 10.1111/j.1398-9995.2011.02647.x. Epub 2011 May 24. PMID: 21605126
Start Year 2011
 
Description GlaxoSmithKline 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Development of an experimental model of rhinovirus induced COPD exacerbation.
Collaborator Contribution Development of an experimental model of rhinovirus induced COPD exacerbation.
Impact ...
 
Description GlaxoSmithKline 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Molecular mechanisms of inhibition by fluticasone, salmeterol and the combination of rhinovirus induction of pro-inflammatory molecules.
Collaborator Contribution Molecular mechanisms of inhibition by fluticasone, salmeterol and the combination of rhinovirus induction of pro-inflammatory molecules.
Impact ...
 
Description GlaxoSmithKline UK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Investigating the effects of combined steroid and ß2 agonist on innate anti-infective immune responses in epithelial cells and macrophages.
Collaborator Contribution Investigating the effects of combined steroid and ß2 agonist on innate anti-infective immune responses in epithelial cells and macrophages.
Impact ....
Start Year 2009
 
Description Impact vitamin D and steroids on regulatory T cells & Th17 subsets 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Complimentary observations in humans systems, providing translational angle to studies;
Collaborator Contribution Complimentary observation in experimental models and in vivo. Development of new intellectual concepts
Impact Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002 Mar 4;195(5):603-16. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005 Apr;5(4):271-83. Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK, Robinson DS, Barrat FJ, O'Garra A, Lavender P, Lee TH, Corrigan C, Hawrylowicz CM. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest. 2006 Jan;116(1):146-55. Epub 2005 Dec 8. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev. 2008 Jun;223:114-31. Urry Z, Chambers ES, Xystrakis E, Dimeloe S, Richards DF, Gabryšová L, Christensen J, Gupta A, Saglani S, Bush A, O'Garra A, Brown Z, Hawrylowicz CM. The role of 1a,25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3+ and IL-10+ CD4+ T cells. Eur J Immunol. 2012 Oct;42(10):2697-708.
 
Description MedImmune Inc USA 
Organisation MedImmune
Country United States 
Sector Private 
PI Contribution Characterisation of a human ICAM-1 transgenic mouse model for determination of the efficacy of anti-ICAM-1 directed mAbs in major group HRV infection and HRV induced asthma exacerbation.
Collaborator Contribution Characterisation of a human ICAM-1 transgenic mouse model for determination of the efficacy of anti-ICAM-1 directed mAbs in major group HRV infection and HRV induced asthma exacerbation.
Impact .....
Start Year 2010
 
Description Microbiome work with Professor W Cookson and Mariam Moffatt 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of samples and of Resaerch Fellow
Collaborator Contribution 16S quantification of microbiota
Impact Papers on microbiome in asthma
Start Year 2014
 
Description Microbiome work with Professor W Cookson and Mariam Moffatt 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of samples and of Resaerch Fellow
Collaborator Contribution 16S quantification of microbiota
Impact Papers on microbiome in asthma
Start Year 2014
 
Description Novartis Collaboration 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution Investigated effects of omalizumab in non-atopic asthma, using a proof of concept clinical study backed by immunohistochemistry from bronchial biopsies.
Collaborator Contribution Intellectual exchange Funding for research fellow Provision of omalizumab and placebo to GCP standard
Impact Manuscript in preparation
Start Year 2010
 
Description Peakdale Molecular - Synthesis of novel LTA4H modulators and ADMET studies of lead compounds 
Organisation Peakdale Molecular
Country United Kingdom 
Sector Private 
PI Contribution I have undertaken a drug development program to develop selective LTA4H inhibitors that will abrogate the pro-inflammatory LTB4-generating activity but preserve the anti-inflammatory PGP-degrading activity of the enzyme. My research team have been integral in the design and testing of these novel inhibitors.
Collaborator Contribution Peakdale Molecular have synthesized compounds that we have designed and also performed ADMET studies on lead compounds. Whilst they have acted as a CRO, they have taken an active interest in the project and provided additional intellectual input and in some instances invested additional hours to this project than for which they have received recompense. As part of the Asthma UK award specifically, we have been able to build on our collaboration with Peakdale whereby they have synthesized conventional LTA4H inhibitors and our novel compounds for testing in pre-clinical animal models.
Impact Our collaboration has led to the development of several selective LTA4H modulators. Through this collaboration, it has been possible to submit 3 successful grant applications: 1. Medical Research Council / Imperial Innovations for award entitled "Manipulating the dual functions of LTA4H: one drug to target two pro-inflammatory mediators tightly implicated in neutrophilic lung disease" (08.2013-04.2014; £56,075). 2. Medical Research Council / Imperial Innovations for award entitled "Manipulating the dual functions of LTA4H: one drug to target two pro-inflammatory mediators - Proof of concept in neutrophilic lung disease models" (06.2014-09.2014; £30,744). 3. Asthma UK Innovations award entitled "The development of superior LTA4H modulators for treatment of allergic airway disease" (10.2014-03.2016; £46,540) As part of the Asthma UK award, the collaboration has enabled us to synthesize large quantities of pure, active LTA4H modulators that have yielded substantial results in pre-clinical animal models of allergic airways disease. We are currently preparing two manuscripts for submission- one on the development of selective compounds (which was in part made possible through the Asthma UK funding) and the second on the role of LTA4H in asthma (which is entirely attributable to funding received from asthma UK)..
Start Year 2012
 
Description Pfizer 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution Development of an experimental model of rhinovirus induced COPD exacerbations.
Collaborator Contribution Development of an experimental model of rhinovirus induced COPD exacerbations.
Impact ...
 
Description Prof Adnan Custovic, Imperial College London 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with Prof Custovic in a study will combining world-leading expertise in infection and immunity, a population based birth cohort study and computational analysis to identify novel mechanisms related to increased susceptibility to asthma, allergies and RTIs.
Collaborator Contribution Collaboration with Prof Custovic in a study will combining world-leading expertise in infection and immunity, a population based birth cohort study and computational analysis to identify novel mechanisms related to increased susceptibility to asthma, allergies and RTIs.
Impact ongoing collaboration
Start Year 2006
 
Description Prof Alberto Papi, University of Ferrara at S.Anna University Hospital 
Organisation University of Ferrara
Country Italy 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Andrew Bush, Imperial College London 
Organisation Imperial College London
Department National Heart & Lung Institute (NHLI)
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Anne Greenough, King's College London 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Chris Brightling, University of Leicester 
Organisation University of Leicester
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Dallas Swallow, UCL 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Ian Sabroe, Sheffield 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Jane Mitchell, Imperial College London 
Organisation Imperial College London
Department National Heart & Lung Institute (NHLI)
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Joerg Mattes, Newcastle 
Organisation University of Newcastle
Country Australia 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Jonathan Grigg, QMUL 
Organisation Queen Mary University of London
Department Blizard Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Lena Uller 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Michael J Holtzman, Washington 
Organisation Washington University in St Louis
Country United States 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Nikos Papadopoulos 
Organisation University of Athens
Country Greece 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Patrick Holt, UWA 
Organisation Telethon Kids Institute
Department Division of Cell Biology
Country Australia 
Sector Charity/Non Profit 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Paul Foster, UCL 
Organisation University of Newcastle
Country Australia 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Peter Sly, UWA 
Organisation University of Queensland
Department Children's Health & Environment Program (CHEP)
Country Australia 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Renaud Louis, Belgium 
Organisation University of Liege
Department Department of Pneumology
Country Belgium 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Prof Rene Lutter, AMC 
Organisation VU University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution ongoing collaboration
Collaborator Contribution ongoing collaboration
Impact ongoing collaboration
 
Description Professor Anne Greenough, King's College London 
Organisation King's College London
Department MRC & Asthma UK Centre in Allergic Mechanisms of Asthma
Country United Kingdom 
Sector Academic/University 
PI Contribution Determining the contribution of premature birth and respiratory viral infections to the development of asthma and chronic respiratory morbidity and identifying preventative measures. In addition, determining the role of asthma in the development of the pulmonary complications of sickle cell disease.
Collaborator Contribution I am a member of ResViNET which combines expertise and leadership to decrease the global burden of RSV infection and develop safe and effective therapeutic and preventative interventions. All of the partners have synergistic expertise regarding the pathophysiology, impact and treatment of RSV infection. My particular expertise is determining the impact of respiratory viruses on the long term outcome of prematurely born infants.
Impact Publications KHP Challenge Grant
 
Description Professor Clare Lloyd - MMP-12 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution We work closely with Professor Lloyd's group when conducting our murine studies and routinely meet to discuss results and plan next steps.
Collaborator Contribution Professor Lloyd is an international leader in asthma and developed physiologically relevant murine models of asthma, which we utilize within our studies.
Impact We are currently preparing a manuscript detailing our studies for publication.
Start Year 2017
 
Description QMUL 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution Joint design and participation in clinical trials of vitamin D treatment in respiratory disease
Collaborator Contribution Expertise in trial design, and vitamin D in respiratory infections
Impact Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-?(high) immunophenotypes: Potential benefits of calcitriol. Chambers ES, Nanzer AM, Pfeffer PE, Richards DF, Timms PM, Martineau AR, Griffiths CJ, Corrigan CJ, Hawrylowicz CM. J Allergy Clin Immunol. 2015 Sep;136(3):628-637 Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs). Martineau AR, MacLaughlin BD, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, Kilpin K, McLaughlin D, Fletcher G, Mein CA, Hoti M, Walton R, Grigg J, Timms PM, Rajakulasingam RK, Bhowmik A, Rowe M, Venton TR, Choudhury AB, Simcock DE, Sadique Z, Monteiro WR, Corrigan CJ, Hawrylowicz CM, Griffiths CJ. Thorax. 2015 May;70(5):451-7. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, Islam K, McLaughlin D, Bhowmik A, Timms PM, Rajakulasingam RK, Rowe M, Venton TR, Choudhury AB, Simcock DE, Wilks M, Degun A, Sadique Z, Monteiro WR, Corrigan CJ, Hawrylowicz CM, Griffiths CJ. Lancet Respir Med. 2015 Feb;3(2):120-30. The effects of calcitriol treatment in glucocorticoid-resistant asthma. Nanzer AM, Chambers ES, Ryanna K, Freeman AT, Colligan G, Richards DF, Timms PM, Martineau AR, Griffiths CJ, Corrigan CJ, Hawrylowicz CM. J Allergy Clin Immunol. 2014 Jun;133(6):1755-7. Enhanced production of IL-17A in patients with severe asthma is inhibited by 1a,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion. Nanzer AM, Chambers ES, Ryanna K, Richards DF, Black C, Timms PM, Martineau AR, Griffiths CJ, Corrigan CJ, Hawrylowicz CM. J Allergy Clin Immunol. 2013 Aug;132(2):297-304. Serum 25-dihydroxyvitamin D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma. Chambers ES, Nanzer AM, Richards DF, Ryanna K, Freeman AT, Timms PM, Martineau AR, Griffiths CJ, Corrigan CJ, Hawrylowicz CM. J Allergy Clin Immunol. 2012 Aug;130(2):542-4.
Start Year 2007
 
Description SD/ Dr W Busse, Inner City Asthma Consortium, NIAID, USA 
Organisation National Institute of Allergy and Infectious Diseases (NIAID)
Country United States 
Sector Public 
PI Contribution Publication
Collaborator Contribution Publication
Impact Wood RA, Togias A, Wildfire J, Visness CM,Matsui E, Liu AH, O'Connor GT, Pongracic J, Little F, Granada M, Kennedy S; DurhamSR, Shamji M, Shreffler W, Busse W. Development of functional IgG antibodies to cockroach. Development of Cockroach Immunotherapy by the Inner City Asthma Consortium. J Allergy Clin Immunol 2012, (submitted).
Start Year 2012
 
Description SD/ Dr Wesley Burks, University of North Carolina Chapel Hill, USA 
Organisation University of North Carolina at Chapel Hill
Department UNC School of Medicine
Country United States 
Sector Academic/University 
PI Contribution Development and validation of functional IgG antibodies to peanut. Manuscript in preparation.
Collaborator Contribution Development and validation of functional IgG antibodies to peanut. Manuscript in preparation.
Impact Future publication
Start Year 2012
 
Description SD/Dr Eva Varga University of Grax, Austria 
Organisation Medical University of Graz
Country Austria 
Sector Academic/University 
PI Contribution Publication
Collaborator Contribution Publication
Impact Varga EM, Kausar F, Aberer W, Zach M, Eber E, Durham SR, Shamji MH. Tolerant beekeepers display venom-specific functional IgG(4) antibodies in the absence of specific IgE. J Allergy Clin Immunol. 2012 Oct 11. doi:pii: S0091-6749(12)01452-2. 10.1016/j.jaci.2012.08.037
Start Year 2012
 
Description SD/Dr Rudi Valenta Medical University of Vienna, Austria 
Organisation Medical University of Vienna
Department Medicine
Country Austria 
Sector Academic/University 
PI Contribution Functional IgG antibody measurements to novel recombinant grass allergens 2012 3 month visiting EAACI fellowship to Imperial College (Dr Kathi Marth)
Collaborator Contribution Functional IgG antibody measurements to novel recombinant grass allergens 2012 3 month visiting EAACI fellowship to Imperial College (Dr Kathi Marth)
Impact Publications: Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010;40:1346-52 Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji M, Layhadi J, Gieras A, Swoboda I, Zafred D?, Keller, Valent P, Durham S Valenta R. A non-allergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG towards IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. Journal of Immunology 2012 (favourably reviewed in final revision)
Start Year 2012
 
Description Sanofi Pasteur France 
Organisation Sanofi Pasteur MSD
Country United Kingdom 
Sector Private 
PI Contribution Use of adjuvants to manipulate immune responses to rhinovirus infections.
Collaborator Contribution Use of adjuvants to manipulate immune responses to rhinovirus infections.
Impact ...
 
Description Severe asthma consortium 
Organisation Medical Research Council (MRC)
Country United Kingdom 
Sector Academic/University 
PI Contribution MRC funded national consortium of severe asthma centres
Collaborator Contribution Collaboration in trials of new biologicals, management strategies for severe asthma
Impact None as yet: recently funded
Start Year 2014
 
Description Task Force on eicosanoids in asthma and allergy, European Academy of Allergy and Clinical Immunology 
Organisation Jagiellonian University
Country Poland 
Sector Academic/University 
PI Contribution Organiser and chair of the Task Force
Collaborator Contribution Starting the collaboration on eicosanoids in asthma and allergy. Working on a consensus report.
Impact n/a
Start Year 2017
 
Description Task Force on eicosanoids in asthma and allergy, European Academy of Allergy and Clinical Immunology 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Organiser and chair of the Task Force
Collaborator Contribution Starting the collaboration on eicosanoids in asthma and allergy. Working on a consensus report.
Impact n/a
Start Year 2017
 
Description Task Force on eicosanoids in asthma and allergy, European Academy of Allergy and Clinical Immunology 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Organiser and chair of the Task Force
Collaborator Contribution Starting the collaboration on eicosanoids in asthma and allergy. Working on a consensus report.
Impact n/a
Start Year 2017
 
Description Task Force on eicosanoids in asthma and allergy, European Academy of Allergy and Clinical Immunology 
Organisation University of Groningen
Country Netherlands 
Sector Academic/University 
PI Contribution Organiser and chair of the Task Force
Collaborator Contribution Starting the collaboration on eicosanoids in asthma and allergy. Working on a consensus report.
Impact n/a
Start Year 2017
 
Description Task Force on eicosanoids in asthma and allergy, European Academy of Allergy and Clinical Immunology 
Organisation University of Milan
Country Italy 
Sector Academic/University 
PI Contribution Organiser and chair of the Task Force
Collaborator Contribution Starting the collaboration on eicosanoids in asthma and allergy. Working on a consensus report.
Impact n/a
Start Year 2017
 
Description Task Force on eicosanoids in asthma and allergy, European Academy of Allergy and Clinical Immunology 
Organisation University of Vienna
Country Austria 
Sector Academic/University 
PI Contribution Organiser and chair of the Task Force
Collaborator Contribution Starting the collaboration on eicosanoids in asthma and allergy. Working on a consensus report.
Impact n/a
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation Aarhus University
Country Denmark 
Sector Academic/University 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation Antwerp University Hospital
Country Belgium 
Sector Hospitals 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation Technical University of Munich
Country Germany 
Sector Academic/University 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation University of Bonn
Country Germany 
Sector Academic/University 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation University of Helsinki
Country Finland 
Sector Academic/University 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation University of Malaga
Country Spain 
Sector Academic/University 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Task-force for the external quality assurance of the basophil activation test 
Organisation Utrecht University
Country Netherlands 
Sector Academic/University 
PI Contribution I have planned the task force and contributed with ideas for the best way forward in the standardisation and quality assurance of the basophil activation test across different centres in Europe. Me and my team have also tested samples that were sent around the various laboratories and provided the results to the group. I have critically analysed the results and interpreted them as we are preparing the manuscript for submission.
Collaborator Contribution The partners in this collaboration have provided data and input from their own centres.
Impact We are now preparing a manuscript for publication and setting up a system with a central european laboratory for quality assurance of the BAT.
Start Year 2017
 
Description Twins study 
Organisation King’s Health Partners
Country United Kingdom 
Sector Academic/University 
PI Contribution Analysis of monozygotic twines for the presence/absence of asthma to discover non-concordant twins for epigenomic analysis
Collaborator Contribution Provide and recruit twins
Impact None as yet: just commenced
Start Year 2013
 
Description University of Manchester - clinical samples from asthmatics 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution We have assessed pathways of relevance within these clinical samples.
Collaborator Contribution Professor Tracy Hussell, Professor Angela Simpson, Dr Robert Niven, Dr Gael Tavernier and Dr Aleksander Grabiec from the University of Manchester were all instrumental in the provision of clinical samples from asthmatics and healthy controls. They have also provided significant input in discussions of clinical relevance of the findings.
Impact The following publication: Patel DF, Peiró T, Shoemark A, Akthar S, Walker SA, Grabiec AM, Jackson PL, Hussell T, Gaggar A, Xu X, Trevor JL, Li J, Steele C, Tavernier G, Blalock JE, Niven RM, Gregory LG, Simpson A, Lloyd CM, Snelgrove RJ. An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness. Sci Transl Med. 2018 Aug 22;10(455).
Start Year 2017
 
Description Vitamin D supplementation in pregnancy: impact on neonatal immune phenotype 
Organisation Boston University
Department Pulmonary, Allergy, Sleep, and Critical Care Medicine
Country United States 
Sector Academic/University 
PI Contribution (1) Immunological analyses of clinical samples from trial. (2) Investigations of effects vitamin D on immune function in early life.
Collaborator Contribution Design and undertaken clinical trial of high dose vitamin D supplementation in pregnancy to assess impact on clinical outcomes relating to asthma in the offspring
Impact Two peer-reviewed papers to date, but more anticipated.
Start Year 2010
 
Description Vitamin D supplementation in pregnancy: impact on neonatal immune phenotype 
Organisation Harvard University
Country United States 
Sector Academic/University 
PI Contribution (1) Immunological analyses of clinical samples from trial. (2) Investigations of effects vitamin D on immune function in early life.
Collaborator Contribution Design and undertaken clinical trial of high dose vitamin D supplementation in pregnancy to assess impact on clinical outcomes relating to asthma in the offspring
Impact Two peer-reviewed papers to date, but more anticipated.
Start Year 2010
 
Title Anti-IgE antibodies 
Description Antibody-derived biologic that inhibits binding of IgE to its receptors on effector cells. 
IP Reference WO2017/211928 A1 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact Understanding of the mechanism of action of anti-IgE antibodies in general and the possibilities for allosteric inhibition.
 
Title PCT Calcilytics and Pro-Inflammatory Lung Disorders 
Description Use of calciltytics for the therapy of obstructive airways diseases 
IP Reference GB Appl 1217330.8 UKIPO SR |0097P/GB| 
Protection Patent application published
Year Protection Granted 2014
Licensed No
Impact None as yet but it is hoped to collaborate with pharma in phase I studies.
 
Title Basophil activation test to peanut 
Description The laboratory technique has been developed and validated for peanut allergy using samples from study ID 10020 in CRN Portfolio. Diagnostic performance and cut-off values have been determined and validated. It is currently being tested and validated to diagnose other food allergies, incluing milk, egg, sesame and cashew nut allergies. I would like to translate it to a clinical laboratory with the view of applying it to clinical practice. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2014
Development Status Under active development/distribution
Clinical Trial? Yes
UKCRN/ISCTN Identifier CRN Portfolio 10020
Impact This test will improve the accuracy of the diagnosis of peanut allergy and reduce the number of oral food challenges to peanut. 
 
Company Name Therapeutic Frontiers Limited 
Description Founded from the National Heart and Lung Institute (NHLI) within Imperial College London (ICL), Therapeutic Frontiers have over 20 years' experience in the infection of human volunteers with rhinovirus (RV). Stemming from the early work of CEO Professor Sebastian L Johnston, the human infection model has been performed successfully in healthy volunteers, asthmatic (including moderate and severe) and COPD patients. 
Year Established 2015 
Impact Uniquely, TF are the only such group worldwide to successfully infect and study severe asthmatic and COPD patients providing a new pipeline to proof of concept clinical trials in relevant patient groups. These progressive human infection models are further enhanced by the scientific experience provided by Dr Michael R Edwards and Dr Ross P Walton who have novel expertise in cellular, molecular and immunological assays, delivering academic excellence to meet and exceed today's industrial expectations.
Website http://www.therapeuticfrontiers.com/
 
Company Name PULMOCIDE LIMITED 
Description Inhaled antibiotics for respiratory synctial virus and Aspergillus fumigatus 
Year Established 2007 
Impact Now into Phase 2 studies. Notable cure of salvage lung transplant aspergillosis in two patients on compassionate use program this month.
 
Description "The Conversation" article on hay fever 2014 (Online). Corrigan CJ. URL: 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact research awareness


research awareness
Year(s) Of Engagement Activity 2014
URL http://theconversation.com/explainer-what-is-hay-fever-and-why-do-you-have-it-27034www.
 
Description 1 day symposium on Vitamin D 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact C Hawrylowicz, organizer with Dr Adrian Martineau and Prof Chris Griffiths of a 1-day international conference on Vitamin D with speakers from UK, European and USA. Preceded by a press conference with all major UK papers present asking panel including organizers on importance vitamin D for human health and guidelines on recommended daily use


Plenty of press coverage on vitamin D, including our ASthma UK funded research (CH, AM, CG)
Martineau/Griffiths in follow up rado 4 interview
Year(s) Of Engagement Activity 2010
 
Description 10e Congrès Francophone d'Allergologie 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Lecture Asthma Exacerbations : New Insights
Year(s) Of Engagement Activity 2015
 
Description 18th British Paediatric Respiratory Society symposium Talk: Respiratory viruses, innate immunity and allergic lung diseases - current state of the art. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact The theme will aim to look at creative ideas, which may be outside the rules of the system ... in respiratory health and disease in children and will present emerging evidence as well as issues in management of Paediatric respiratory disease.
Year(s) Of Engagement Activity 2016
 
Description 2014 - Jeffrey M Drazen Visiting Professor at Partners Asthma Center - Boston 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Health professionals
Results and Impact Talk on Etiology and mechanisms of exacerbations of asthma and COPD led to discussion

share information
Year(s) Of Engagement Activity 2014
 
Description 2014 - Journees de Recherche Respiratoire 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact talk on Viral infection and asthma led to discussion

Shared knowledge
Year(s) Of Engagement Activity 2014
 
Description 2018 MRC Max Perutz Science Writing Awards - student shortlisted 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact One of the Centre students, Gesa Albers, was shortlisted for the MRC's 2018 Max Perutz Science Writing Award with her short essay, written for a non-scientific audience, about her research: "Immune cell diet, cure for asthma?".
Year(s) Of Engagement Activity 2018
URL https://mrc.ukri.org/news/browse/2018-max-perutz-shortlist/
 
Description 21st Vitamin D Workshop - International 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact 21st Vitamin D Workshop
Year(s) Of Engagement Activity 2018
 
Description 4th World Equine Airway Symposium, Berne Switzerland, 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact To give an overview of infections in human asthma, and what we have learnt about innate host responses.
To learn about horse asthma, and understand similarities with human disease.
Year(s) Of Engagement Activity 2008,2009
 
Description 5th DZL International Symposium - Talk: Mechanisms of virus induced asthma exacerbations and their therapeutic implications 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact General aspects of chronic obstructive diseases. New research and development in COPD.
Year(s) Of Engagement Activity 2016
 
Description 6th form talks and workshops at schools (Sutton): 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact 6th form talks and workshops at schools (Sutton):
Brighton College (1/10/13)
St. Paul's School, London (20/1/14)
Oxford Schools (at History of Science Museum, Oxford; 14/3/14)
Brighton College (11/9/14)


awareness
Year(s) Of Engagement Activity 2014
 
Description A-Level students' work experience - Belvisi lab 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Three A-Level students participated in a work experience project in the laboratory for a week during their summer break.
Year(s) Of Engagement Activity 2016
 
Description AC - Visit to Asthma UK to publicise the work of the STELAR consortium 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Third sector organisations
Results and Impact Visit to Asthma UK to publicise the work of the STELAR consortium
Year(s) Of Engagement Activity 2017
 
Description AG - Contributed to a newspaper article and had radio coverage following there NEJM publication 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact awareness

n/a
Year(s) Of Engagement Activity 2014
 
Description AG - statement to Trust Chief Execs on paediatrician participation on ethics committees 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact The Group have worked with the Nuffield Council to produce a statement sent to all Trust Chief Executives emphasising the importance of paediatricians having their time to be part of Ethics committees valued, and surveyed paediatricians involvement in patient and public engagement.
Year(s) Of Engagement Activity 2017
 
Description AJ - Presented at ERS Congress 2016 - 'Asthma patients hospitalized with influenza lack mucosal and systemic type 2 inflammation'. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AJ delivered a presentation titled 'Asthma patients hospitalized with influenza lack mucosal and systemic type 2 inflammation' at the ERS Congress 2016, as part of an Oral Presentation session called 'Molecular Immunology of the Lung'.
Year(s) Of Engagement Activity 2016
URL http://www.ers-education.org/events/international-congress/london-2016.aspx?idParent=151892
 
Description ATS (New Orleans, USA, 2010) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Foremost international respiratory conference organized by the American Thoracic Society (rough estimate of attendance 10,000)
Hawrylowicz, symposium speaker on "Vitamin D". Wide scientific interactions with clinicians, scientists, trainees, collaborators

Well attended high profile conference providing high visibility of Asthma UK funded resarach and MRC/Asthma UK Centre
Year(s) Of Engagement Activity 2010
 
Description ATS - Talk: Where Next in Asthma Research? 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A Review of Current Understanding and Future Focus to Prevent and Cure Asthma
Year(s) Of Engagement Activity 2016
 
Description ATS Annual Meeting - Presentation: "Short and Long-Term Effects of Viruses Versus Bacteria on Immune Responses in Asthma" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A Review of Current Understanding and Future Focus to Prevent and Cure Asthma
Year(s) Of Engagement Activity 2017
 
Description AUKCAR - MRC Mechanism Centre joint Postgraduate training day. The translational research pipeline. Closing the T1/T2 gap. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact With T1 translational research, findings from basic research are tested for clinical effect and/or applicability. T1 yields knowledge about human physiology and the potential for intervention.
With T2 translational research, investigators test new interventions under controlled environments to form the basis for clinical application and evidence-based guidelines.
With T3 translational research, investigators explore ways of applying recommendations or guidelines in general practice.
With T4 translational research, investigators study factors and interventions that influence the health populations.
Year(s) Of Engagement Activity 2016
 
Description American Thoracic Society 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Lecture Viruses and Asthmatic Airways
Year(s) Of Engagement Activity 2015
 
Description Appearamnce on BBC Radio 4's File on 4 - "Car emissions - coming clean?" 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Appeared on BBC Radio 4's File on 4 - "Car emissions - coming clean?"
Year(s) Of Engagement Activity 2017
 
Description April 2014 - Society for General Microbiology Annual Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Led to discussion

Further develop knowledge
Year(s) Of Engagement Activity 2014
 
Description Article on BBC Expert Network 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Article for the BBC Expert Network about the recent increase in food allergy and possible explanations for this.
Year(s) Of Engagement Activity 2018
URL https://www.bbc.com/news/health-46302780?fbclid=IwAR0KdB97TFPdhxl_-oZ4hceUlV4VsOLcjA8csUxua9FnxLUkx9...
 
Description Asthma Sympsosium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A presentation at the Scottish Allergy & Respiratory Academy (SARA) in Edinburgh, November 2016. Title of the talk was "Innate immunity to rhinovirus & asthma exacerbations"
Year(s) Of Engagement Activity 2016
URL https://www.cyans.org.uk/paediatric-allergy-group
 
Description Asthma UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Participated at Asthma UK Conference and gave a talk titled "Curing and preventing asthma; where do we go next?"
Year(s) Of Engagement Activity 2018
 
Description Asthma UK Event 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Supporters
Results and Impact 50 potential donors and members of the public attended this event, where PI and post-doctoral researchers presented about their research and showed them around the laboratories and research facilities. This event was very successful and significantly contributed for the funds needed for the renovation of the 5-year funding period of the centre.
Year(s) Of Engagement Activity 2015
 
Description Asthma UK Fundraiser staff visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Fundraiser staff (16 people) spend a morning in the Faculty. Meeting Scientist, visiting the labs and looking at cells through a microscope. Opportunity to explain our research to a lay audience.
Year(s) Of Engagement Activity 2015
 
Description Asthma UK Fundraising Event 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact About 25 people who were either patients, relatives of patients or general public interested in asthma and allergy visited the department and the labs and had the opportunity to hear about recent research findings in asthma and allergy and had the opportunity to ask questions to the researchers and their teams. The event was organised by Asthma UK and raised interest and donations to this charity as a consequence.
Year(s) Of Engagement Activity 2012,2016,2017,2018
 
Description Asthma UK Publicity materials 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Interview (recorded and filmed) for use by Asthma UK for fundraising and asthma awareness campaign.
Year(s) Of Engagement Activity 2016
 
Description Asthma UK site visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Talk initiated questions and discussion and gave a greater understanding to a lay audience

Asthma UK staff felt better informed about the challenges associated with research at an academic institution and how they may assist us in clinical reseaerch.
Year(s) Of Engagement Activity 2014
 
Description Asthma magazine profile 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? Yes
Type Of Presentation Paper Presentation
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Widely read website by asthma patients, families and friends, journalists, policy makers etc

Difficullt to assess, but presumably widespread
Year(s) Of Engagement Activity 2009
 
Description Ataxia-Telangiectasia Society - AB 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact Ataxia-Telangiectasia Society: I was invited to join the charity (http://www.atsociety.org.uk/) for the bimonthly supraregional specialist clinic, which I attend in my own time and at my own expense. I have spoken at a Charity study day, and instigated the setting up of a European Respiratory Society Task Force on the respiratory management.

awareness
Year(s) Of Engagement Activity 2014
 
Description Atlas Project 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Interview about X-ray crystallography, crystallisation and structure analysis; reference to our work on antibodies in allergy and asthma.
Year(s) Of Engagement Activity 2018
 
Description BBC Health article on allergies 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Dr Alexandra Santos wrote a piece for the BBC Health pages about allergies: "Why the world is becoming more allergic to food." It was a general magazine piece (rather than focusing on a particular study in the news) and looked at the increasing rates of food allergy, what we know about food allergies, and what researchers are investigating to find out more.
Year(s) Of Engagement Activity 2018
URL https://www.bbc.co.uk/news/health-46302780
 
Description BBC Radio 4 interview - 4 You and Yours 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Professor Frank Kelly was interviewed for a feature on the benefits of wearing anti-pollution masks in order to prevent respiratory illness.
Year(s) Of Engagement Activity 2017